48_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 1_CD Accounting_NNP policies_NNS Foreign_JJ currency_NN transactions_NNS Foreign_JJ currency_NN transactions_NNS by_IN Group_NNP companies_NNS are_VBP recorded_VBN in_IN local_JJ Accounting_NN convention_NN and_CC presentation_NN currency_NN at_IN the_DT exchange_NN rate_NN ruling_NN on_IN the_DT date_NN of_IN transaction_NN ._.
Assets_NNS and_CC The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN under_IN the_DT historical_JJ cost_NN liabilities_NNS expressed_VBN in_IN foreign_JJ currencies_NNS are_VBP translated_VBN into_IN sterling_NN at_IN the_DT convention_NN and_CC in_IN accordance_NN with_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC applicable_JJ exchange_NN rates_NNS ruling_VBG at_IN the_DT balance_NN sheet_NN date_NN ._.
Exchange_NNP differences_NNS which_WDT UK_NNP accounting_NN standards_NNS ._.
The_DT principal_JJ accounting_NN policies_NNS have_VBP been_VBN relate_VBP to_TO the_DT retranslation_NN of_IN net_JJ assets_NNS of_IN overseas_JJ companies_NNS are_VBP taken_VBN applied_VBN consistently_RB and_CC are_VBP set_VBN out_RP below_IN ._.
The_DT results_NNS for_IN the_DT year_NN all_DT relate_VBP directly_RB to_TO reserves_NNS ._.
All_DT other_JJ foreign_JJ exchange_NN differences_NNS are_VBP taken_VBN to_TO the_DT to_TO continuing_VBG operations_NNS ._.
The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_JJ profit_NN and_CC loss_NN account_NN in_IN the_DT year_NN in_IN which_WDT they_PRP arise_VBP ._.
The_DT Group_NNP uses_VBZ the_DT on_IN a_DT going_VBG concern_NN basis_NN ._.
average_JJ exchange_NN rates_NNS prevailing_VBG during_IN the_DT year_NN to_TO translate_VB the_DT results_NNS of_IN overseas_JJ subsidiaries_NNS into_IN sterling_NN and_CC year-end_NN rates_NNS to_TO translate_VB the_DT net_JJ During_IN 2004_CD the_DT Group_NNP has_VBZ implemented_VBN UITF_NNP Abstract_NNP 38_CD :_: Accounting_NNP assets_NNS of_IN those_DT undertakings_NNS ._.
for_IN ESOP_NNP trusts_NNS and_CC related_JJ amendments_NNS to_TO Abstract_NNP 17_CD :_: Employee_NN share_NN schemes_NNS ._.
UITF_NNP 38_CD changes_NNS the_DT presentation_NN of_IN an_DT entitys_JJ own_JJ shares_NNS held_VBD Pension_NN costs_NNS in_IN an_DT ESOP_NNP trust_NN from_IN requiring_VBG them_PRP to_TO be_VB recognized_VBN as_IN assets_NNS to_TO requiring_VBG The_DT costs_NNS of_IN the_DT Groups_NNS defined_VBN contribution_NN pension_NN arrangements_NNS are_VBP them_PRP to_TO be_VB deducted_VBN in_IN arriving_VBG at_IN shareholders_NNS funds_NNS ._.
UITF_NNP 17_CD revised_VBN charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN the_DT year_NN to_TO which_WDT they_PRP relate_VBP ._.
The_DT requires_VBZ that_IN the_DT minimum_JJ expense_NN recognized_VBN in_IN respect_NN of_IN an_DT award_NN should_MD costs_NNS of_IN the_DT Groups_NNS defined_VBN benefits_NNS scheme_NN are_VBP charged_VBN on_IN a_DT systematic_JJ be_VB the_DT difference_NN between_IN the_DT fair_JJ value_NN of_IN the_DT shares_NNS at_IN the_DT date_NN of_IN award_NN and_CC basis_NN allowing_VBG for_IN the_DT expected_VBN pension_NN cost_NN over_IN the_DT service_NN lives_NNS of_IN the_DT amount_NN that_IN an_DT employee_NN may_MD be_VB required_VBN to_TO pay_VB for_IN the_DT shares_NNS i._VBP e._VB the_DT employees_NNS ,_, based_VBN on_IN actuarial_JJ advice_NN ._.
intrinsic_JJ value_NN of_IN the_DT award_NN ._.
The_DT prior_JJ year_NN comparatives_NNS have_VBP been_VBN restated_VBN for_IN the_DT adoption_NN of_IN UITF_NNP Abstract_NNP 38_CD ._.
The_DT effect_NN of_IN adoption_NN of_IN UITF_NNP 17_CD is_VBZ Employee_NNP share_NN plans_VBZ not_RB material_NN ._.
Incentives_NNS in_IN the_DT form_NN of_IN shares_NNS are_VBP provided_VBN to_TO employees_NNS under_IN share_NN option_NN and_CC share_NN award_NN schemes_NNS ._.
In_IN respect_NN of_IN award_NN schemes_NNS the_DT Group_NNP provides_VBZ Consolidation_NN finance_NN to_TO an_DT employee_NN share_NN ownership_NN trust_NN to_TO purchase_VB company_NN shares_NNS The_DT consolidated_JJ financial_JJ information_NN includes_VBZ the_DT financial_JJ statements_NNS for_IN on_IN the_DT open_JJ market_NN to_TO meet_VB the_DT Groups_NNS obligation_NN to_TO provide_VB shares_NNS when_WRB the_DT Company_NN and_CC its_PRP$ subsidiary_NN undertakings_NNS ._.
Intra-group_JJ sales_NNS and_CC profits_NNS are_VBP employees_NNS exercise_VBP their_PRP$ award_NN ._.
The_DT difference_NN between_IN the_DT fair_JJ value_NN of_IN the_DT eliminated_VBN fully_RB on_IN consolidation_NN ._.
The_DT results_NNS of_IN subsidiaries_NNS sold_VBN or_CC acquired_VBN shares_NNS at_IN the_DT date_NN of_IN award_NN and_CC the_DT amount_NN that_IN an_DT employee_NN may_MD be_VB required_VBN are_VBP included_VBN in_IN the_DT consolidated_JJ profit_NN and_CC loss_NN account_VBP up_RP to_TO the_DT date_NN of_IN their_PRP$ to_TO pay_VB for_IN the_DT shares_NNS i._VBP e._VB the_DT intrinsic_JJ value_NN of_IN the_DT award_NN is_VBZ charged_VBN ,_, or_CC sale_NN or_CC from_IN their_PRP$ date_NN of_IN acquisition_NN respectively_RB ._.
credited_VBN ,_, to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT periods_NNS of_IN service_NN in_IN respect_NN of_IN which_WDT the_DT award_NN was_VBD granted_VBN ._.
The_DT costs_NNS of_IN running_VBG the_DT employee_NN share_NN Revenue_NN recognition_NN ownership_NN trust_NN are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN they_PRP accrue_VBP ._.
Turnover_NN comprises_VBZ contract_NN development_NN and_CC licensing_NN ,_, royalty_NN and_CC manufacturing_NN and_CC distribution_NN income_NN ._.
Contract_NN development_NN and_CC licensing_NN Shares_NNS held_VBN by_IN the_DT employee_NN share_NN ownership_NN trust_NN are_VBP deducted_VBN from_IN income_NN represents_VBZ amounts_NNS invoiced_VBD to_TO customers_NNS for_IN services_NNS rendered_VBN shareholders_NNS funds_NNS ._.
under_IN development_NN and_CC licensing_NN agreements_NNS ,_, including_VBG milestone_NN payments_NNS and_CC technology_NN access_NN fees_NNS ._.
Contract_NN revenue_NN is_VBZ recognized_VBN when_WRB earned_VBN and_CC Intangible_JJ fixed_VBN assets_NNS non-refundable_JJ and_CC to_TO the_DT extent_NN that_IN there_EX are_VBP no_DT future_JJ obligations_NNS pursuant_JJ Intangible_NNP fixed_VBN assets_NNS comprise_VBP goodwill_NN ,_, intellectual_JJ property_NN and_CC capitalized_VBN to_TO the_DT revenue_NN ,_, in_IN accordance_NN with_IN the_DT contract_NN terms_NNS ._.
Goodwill_NNP ,_, being_VBG the_DT difference_NN between_IN the_DT fair_JJ value_NN of_IN the_DT revenue_NN is_VBZ treated_VBN as_IN deferred_VBN until_IN such_JJ time_NN as_IN it_PRP is_VBZ no_RB longer_RBR refundable_JJ ._.
purchase_NN consideration_NN and_CC the_DT Groups_NNS share_NN of_IN the_DT fair_JJ value_NN of_IN the_DT net_JJ assets_NNS Royalty_NN income_NN represents_VBZ income_NN earned_VBD as_IN a_DT percentage_NN of_IN product_NN sales_NNS ._.
acquired_VBN ,_, is_VBZ capitalized_VBN and_CC amortised_VBN over_IN a_DT period_NN of_IN 20_CD years_NNS or_CC less_JJR in_IN line_NN Advance_NNP royalties_NNS received_VBD are_VBP treated_VBN as_IN deferred_JJ income_NN until_IN earned_VBN ,_, at_IN with_IN the_DT Directors_NNS view_NN of_IN its_PRP$ useful_JJ economic_JJ life_NN ._.
Prior_RB to_TO the_DT introduction_NN which_WDT time_NN they_PRP are_VBP recognized_VBN as_IN income_NN ._.
Manufacturing_NNP and_CC distribution_NN of_IN FRS_NNP 10_CD :_: Goodwill_NNP and_CC intangible_JJ assets_NNS ,_, the_DT policy_NN adopted_VBN was_VBD to_TO write_VB off_RP revenues_NNS principally_RB comprise_VBP contract_NN manufacturing_NN fees_NNS invoiced_VBD to_TO third_JJ goodwill_NN to_TO reserves_NNS ._.
As_IN permitted_VBN by_IN FRS_NNP 10_CD goodwill_NN written_VBN off_RP to_TO reserves_NNS in_IN parties_NNS and_CC income_NN from_IN product_NN sales_NNS ._.
Sales_NNS taxes_NNS are_VBP excluded_VBN from_IN revenue_NN ._.
previous_JJ years_NNS has_VBZ not_RB been_VBN reinstated_VBN on_IN the_DT balance_NN sheet_NN and_CC adjustments_NNS to_TO such_JJ goodwill_NN have_VBP been_VBN taken_VBN directly_RB to_TO reserves_NNS ._.
Goodwill_NN previously_RB Research_NNP and_CC development_NN costs_NNS written_VBN off_RP to_TO reserves_NNS is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN the_DT event_NN Research_NN and_CC development_NN costs_NNS are_VBP charged_VBN as_IN an_DT expense_NN in_IN the_DT period_NN of_IN disposal_NN of_IN the_DT related_JJ business_NN ._.
in_IN which_WDT they_PRP are_VBP incurred_VBN ._.
Intellectual_NNP property_NN comprises_VBZ acquired_VBN patents_NNS ,_, trade_NN marks_NNS ,_, know-how_NN and_CC other_JJ similarly_RB identified_VBN rights_NNS ._.
These_DT are_VBP recorded_VBN at_IN their_PRP$ fair_JJ value_NN at_IN acquisition_NN date_NN and_CC are_VBP amortised_VBN in_IN equal_JJ instalments_NNS over_IN their_PRP$ estimated_VBN useful_JJ economic_JJ lives_NNS ,_, from_IN the_DT date_NN when_WRB the_DT transfer_NN of_IN technology_NN is_VBZ complete_JJ ._.
The_DT period_NN over_IN which_WDT the_DT Group_NNP expects_VBZ to_TO derive_VB economic_JJ benefits_NNS does_VBZ not_RB exceed_VB 20_CD years_NNS ._.
Costs_NNS associated_VBN with_IN internally_RB developed_VBN intellectual_JJ property_NN are_VBP generally_RB treated_VBN as_IN research_NN and_CC development_NN costs_NNS ._.
2004_CD SkyePharma_NNP Annual_JJ Report_NNP 49_CD 1_CD Accounting_NN policies_NNS continued_VBD Leased_JJ and_CC hired_VBD assets_NNS Leasing_NNP agreements_NNS which_WDT transfer_VBP to_TO the_DT Group_NNP substantially_RB all_DT of_IN the_DT risks_NNS Tangible_JJ fixed_VBN assets_NNS and_CC rewards_NNS of_IN ownership_NN of_IN an_DT asset_NN are_VBP treated_VBN as_IN finance_NN leases_NNS ._.
The_DT assets_NNS Tangible_JJ fixed_VBN assets_NNS are_VBP included_VBN in_IN the_DT balance_NN sheet_NN at_IN cost_NN less_JJR are_VBP included_VBN in_IN tangible_JJ fixed_JJ assets_NNS and_CC the_DT capital_NN element_NN of_IN amounts_NNS owed_VBN accumulated_VBN depreciation_NN ._.
Depreciation_NN is_VBZ provided_VBN on_IN tangible_JJ fixed_JJ assets_NNS to_TO the_DT finance_NN company_NN at_IN the_DT balance_NN sheet_NN date_NN is_VBZ included_VBN in_IN creditors_NNS as_IN at_IN rates_NNS calculated_VBN to_TO write_VB off_RP the_DT cost_NN ,_, less_JJR estimated_VBN residual_JJ value_NN ,_, of_IN amounts_NNS falling_VBG due_JJ either_CC within_IN or_CC after_IN more_JJR than_IN one_CD year_NN ._.
Repayments_NNS each_DT asset_NN over_IN its_PRP$ expected_VBN useful_JJ life_NN ._.
The_DT rates_NNS and_CC bases_NNS are_VBP as_IN follows_VBZ :_: are_VBP treated_VBN as_IN consisting_VBG of_IN both_DT capital_NN and_CC interest_NN with_IN the_DT interest_NN element_NN being_VBG charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN proportion_NN to_TO the_DT outstanding_JJ Freehold_NNP land_NN not_RB depreciated_VBD obligations_NNS ._.
Payments_NNS under_IN operating_VBG leases_NNS and_CC short-term_JJ hire_NN contracts_NNS Freehold_NNP buildings_NNS 2_CD %_NN 5_CD %_NN straight_JJ line_NN are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN they_PRP fall_VBP due_JJ ._.
Short_JJ leasehold_NN property_NN period_NN of_IN lease_NN Laboratory_NN equipment_NN and_CC machines_NNS 10_CD %_NN 33_CD %_NN straight_JJ line_NN Convertible_JJ debt_NN Office_NNP and_CC other_JJ equipment_NN 10_CD %_NN 33_CD %_NN straight_JJ line_NN On_IN issue_NN ,_, convertible_JJ debt_NN is_VBZ stated_VBN at_IN the_DT amount_NN of_IN net_JJ proceeds_NNS after_IN Motor_NNP vehicles_NNS 20_CD %_NN straight_JJ line_NN deducting_VBG issue_NN costs_NNS ._.
On_IN conversion_NN ,_, the_DT amount_NN recognized_VBN in_IN shareholders_NNS Finance_NNP leases_VBZ period_NN of_IN lease_NN funds_NNS in_IN respect_NN of_IN the_DT shares_NNS issued_VBN is_VBZ equal_JJ to_TO the_DT carrying_VBG value_NN at_IN the_DT date_NN of_IN conversion_NN ._.
Issue_NN costs_NNS on_IN convertible_JJ debt_NN and_CC any_DT discount_NN on_IN issue_NN are_VBP Fixed_VBN asset_NN investments_NNS Investments_NNP in_IN associates_NNS charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN at_IN a_DT constant_JJ rate_NN over_IN the_DT term_NN of_IN Investments_NNP in_IN associated_VBN undertakings_NNS are_VBP recorded_VBN in_IN the_DT consolidated_JJ the_DT debt_NN ._.
balance_NN sheet_NN at_IN the_DT Groups_NNS share_NN of_IN net_JJ assets_NNS at_IN acquisition_NN and_CC of_IN their_PRP$ post_NN acquisition_NN retained_VBD profits_NNS or_CC losses_NNS ,_, together_RB with_IN any_DT goodwill_NN arising_VBG Deferred_JJ consideration_NN on_IN the_DT acquisition_NN net_NN of_IN amortisation_NN ._.
Goodwill_NN is_VBZ capitalized_VBN and_CC amortised_VBN Provisions_NNS for_IN deferred_JJ consideration_NN comprise_VBP the_DT fair_JJ value_NN of_IN contingent_NN over_IN a_DT period_NN of_IN 20_CD years_NNS or_CC less_JJR in_IN line_NN with_IN the_DT Directors_NNS view_NN of_IN its_PRP$ useful_JJ consideration_NN arising_VBG from_IN acquisitions_NNS ._.
The_DT eventual_JJ outcome_NN is_VBZ subject_JJ to_TO economic_JJ life_NN ._.
the_DT Groups_NNS future_JJ performance_NN and_CC certain_JJ contractual_JJ terms_NNS ._.
Provisions_NNS are_VBP reviewed_VBN annually_RB by_IN the_DT Directors_NNS ,_, and_CC changes_NNS to_TO the_DT estimated_VBN fair_JJ value_NN Fixed_VBN asset_NN investments_NNS Unlisted_JJ investments_NNS of_IN the_DT contingent_JJ consideration_NN are_VBP recorded_VBN as_IN an_DT adjustment_NN to_TO goodwill_NN Investments_NNP that_WDT are_VBP held_VBN for_IN continuing_VBG use_NN in_IN the_DT business_NN are_VBP classified_VBN or_CC the_DT underlying_JJ asset_NN value_NN ._.
as_IN fixed_VBN asset_NN investments_NNS and_CC recorded_VBN in_IN the_DT balance_NN sheet_NN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
Deferred_JJ taxation_NN Deferred_VBN taxation_NN is_VBZ provided_VBN on_IN timing_NN differences_NNS which_WDT at_IN the_DT balance_NN sheet_NN Fixed_VBN asset_NN investments_NNS Shares_NNS in_IN Group_NNP undertakings_NNS date_NN result_NN in_IN an_DT obligation_NN to_TO pay_VB more_JJR tax_NN or_CC a_DT right_NN to_TO pay_VB less_JJR tax_NN at_IN a_DT future_JJ Investments_NNPS in_IN subsidiary_NN undertakings_NNS are_VBP recorded_VBN in_IN the_DT Company_NN balance_NN date_NN ,_, at_IN rates_NNS expected_VBN to_TO apply_VB when_WRB they_PRP crystallise_VBP based_VBN on_IN current_JJ tax_NN sheet_NN at_IN cost_NN ._.
Deferred_JJ tax_NN assets_NNS are_VBP recognized_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ regarded_VBN as_IN more_RBR likely_JJ than_IN not_RB that_IN they_PRP will_MD be_VB recovered_VBN ._.
Deferred_JJ tax_NN Impairment_NN of_IN fixed_JJ assets_NNS assets_NNS and_CC liabilities_NNS are_VBP not_RB discounted_VBN ._.
The_DT carrying_VBG values_NNS of_IN fixed_JJ assets_NNS are_VBP reviewed_VBN for_IN impairment_NN when_WRB there_EX is_VBZ an_DT indication_NN that_IN the_DT assets_NNS may_MD be_VB impaired_VBN ._.
First_JJ year_NN impairment_NN reviews_VBZ Financial_NNP Instruments_NNP are_VBP conducted_VBN for_IN acquired_VBN goodwill_NN and_CC intangible_JJ assets_NNS ._.
Impairment_NN is_VBZ The_DT Group_NNP uses_VBZ derivative_JJ financial_JJ instruments_NNS to_TO hedge_VB its_PRP$ exposure_NN to_TO determined_VBN by_IN reference_NN to_TO the_DT higher_JJR of_IN net_JJ realisable_JJ value_NN and_CC value_NN in_IN use_NN ,_, fluctuations_NNS in_IN interest_NN and_CC foreign_JJ exchange_NN rates_NNS ._.
Specifically_RB ,_, the_DT Group_NNP which_WDT is_VBZ measured_VBN by_IN reference_NN to_TO discounted_JJ future_JJ cash_NN flows_NNS ._.
Any_DT provision_NN uses_VBZ interest_NN rate_NN swaps_NNS ,_, forward_RB currency_NN contracts_NNS and_CC currency_NN options_NNS ._.
for_IN impairment_NN is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN the_DT year_NN concerned_VBN ._.
Receipts_NNPS and_CC payments_NNS on_IN interest_NN rate_NN swaps_NNS are_VBP recognized_VBN on_IN an_DT accruals_NNS basis_NN ,_, over_IN the_DT life_NN of_IN the_DT swap_NN ,_, as_IN an_DT adjustment_NN to_TO interest_NN payable_JJ ._.
Stock_NNP and_CC work-in-progress_JJ Gains_NNS and_CC losses_NNS on_IN forward_JJ currency_NN contracts_NNS and_CC currency_NN options_NNS are_VBP not_RB Stock_NNP and_CC work-in-progress_NN are_VBP valued_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ recognized_VBN until_IN the_DT period_NN that_IN the_DT foreign_JJ currency_NN exposure_NN is_VBZ recognized_VBN ._.
value_NN and_CC calculated_VBN using_VBG the_DT first-in_NN ,_, first-out_JJ basis_NN ._.
Option_NN premia_NN are_VBP deferred_VBN in_IN the_DT balance_NN sheet_NN and_CC recognized_VBN upon_IN the_DT maturity_NN of_IN the_DT option_NN agreement_NN ._.
Current_JJ asset_NN investments_NNS Investments_NNP held_VBD other_JJ than_IN for_IN continuing_VBG use_NN in_IN the_DT business_NN are_VBP classified_VBN Future_JJ requirements_NNS as_IN current_JJ asset_NN investments_NNS and_CC recorded_VBN in_IN the_DT balance_NN sheet_NN at_IN the_DT lower_JJR In_IN June_NNP 2002_CD ,_, the_DT Council_NNP of_IN the_DT European_NNP Union_NNP adopted_VBD a_DT Regulation_NN of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
requiring_VBG listed_VBN companies_NNS in_IN its_PRP$ Member_NNP States_NNPS to_TO prepare_VB consolidated_JJ financial_JJ statements_NNS in_IN accordance_NN with_IN International_NNP Financial_NNP Reporting_NNP Liquid_NN resources_NNS Standards_NNP IFRS_NNP from_IN 1_CD January_NNP 2005_CD ._.
Liquid_NN resources_NNS comprise_VBP short-term_JJ bank_NN and_CC commercial_JJ deposits_NNS with_IN a_DT maturity_NN of_IN less_JJR than_IN one_CD year_NN ._.
The_DT Group_NNP is_VBZ completing_VBG a_DT project_NN to_TO convert_VB its_PRP$ principal_JJ financial_JJ reporting_NN from_IN UK_NNP GAAP_NNP to_TO IFRS_NNP ,_, and_CC plans_VBZ to_TO announce_VB the_DT financial_JJ effect_NN and_CC status_NN of_IN the_DT transition_NN during_IN the_DT first_JJ half_NN of_IN 2005_CD ._.
The_DT first_JJ SkyePharma_NNP financial_JJ statements_NNS prepared_VBN under_IN IFRS_NNP will_MD be_VB for_IN the_DT interim_JJ period_NN ending_VBG 30_CD June_NNP 2005_CD ._.
50_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 2_CD Segmental_JJ analysis_NN The_DT Groups_NNS operations_NNS relate_VBP wholly_RB to_TO one_CD class_NN of_IN business_NN ,_, pharmaceuticals_NNS ._.
Further_JJ analysis_NN of_IN turnover_NN ,_, loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN and_CC net_JJ assets_NNS by_IN geographical_JJ area_NN is_VBZ set_VBN out_RP below_IN ,_, together_RB with_IN an_DT analysis_NN of_IN cost_NN of_IN sales_NNS ._.
Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000_CD a_DT Turnover_NN By_IN class_NN of_IN business_NN :_: Pharmaceuticals_NNP Contract_NNP development_NN and_CC licensing_NN Milestone_NN payments_NNS 20,334_CD 24,196_CD Research_NNP and_CC development_NN costs_NNS recharged_VBD 6,003_CD 5,456_CD 26,337_CD 29,652_CD Royalties_NNS receivable_JJ 25,959_CD 18,701_CD Manufacturing_NNP and_CC distribution_NN 9,872_CD 4,799_CD 62,168_CD 53,152_CD By_IN location_NN of_IN customer_NN :_: UK_NNP 15,343_CD 21,327_CD Europe_NNP 24,875_CD 18,027_CD North_NNP America_NNP 17,195_CD 10,289_CD Rest_VBP of_IN the_DT world_NN 4,755_CD 3,509_CD 62,168_CD 53,152_CD By_IN location_NN of_IN operation_NN :_: Europe_NNP 47,525_CD 42,503_CD North_NNP America_NNP 14,643_CD 10,649_CD 62,168_CD 53,152_CD Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000_CD b_NN Cost_NN of_IN sales_NNS By_IN class_NN of_IN business_NN :_: Pharmaceuticals_NNP Contract_NNP development_NN and_CC licensing_NN 10,735_CD 12,085_CD Royalties_NNS payable_JJ 4,503_CD 4,707_CD Manufacturing_NNP and_CC distribution_NN 15,916_CD 12,994_CD 31,154_CD 29,786_CD 2004_CD SkyePharma_NNP Annual_JJ Report_NNP 51_CD 2_CD Segmental_JJ analysis_NN continued_VBD Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000_CD c_NN Loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN By_IN class_NN of_IN business_NN :_: Pharmaceuticals_NNP 24,048_CD 42,983_CD By_IN location_NN of_IN operation_NN :_: UK_NNP 7,505_CD 5,825_CD Europe_NNP 687_CD 3,424_CD North_NNP America_NNP Operations_NNP 11,856_CD 30,270_CD Associated_NNP undertakings_NNS 10_CD Loss_NN on_IN ordinary_JJ activities_NNS before_IN interest_NN and_CC taxation_NN 18,684_CD 39,519_CD Net_JJ interest_NN payable_JJ 5,364_CD 3,464_CD Loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 24,048_CD 42,983_CD 31_CD December_NNP 2003_CD 31_CD December_NNP 2004_CD restated_VBN 000_CD 000_CD d_SYM Net_JJ assets_NNS By_IN class_NN of_IN business_NN :_: Pharmaceuticals_NNP 63,623_CD 84,870_CD By_IN location_NN of_IN operation_NN :_: UK_NNP 124,493_CD 144,332_CD Europe_NNP 73,736_CD 70,739_CD North_NNP America_NNP Operations_NNP 1,460_CD 11,277_CD Associated_NNP undertakings_NNS 14,326_CD 63,623_CD 84,870_CD 3_CD Other_JJ operating_NN income_NN The_DT Group_NNP entered_VBD into_IN two_CD transactions_NNS with_IN Paul_NNP Capital_NNP Royalty_NNP Acquisition_NNP Fund_NNP in_IN 2000_CD and_CC 2002_CD ._.
Under_IN the_DT first_JJ of_IN these_DT transactions_NNS Paul_NNP Capital_NNP provided_VBD a_DT total_NN of_IN $_$ 30_CD million_CD between_IN 2000_CD and_CC 2002_CD ,_, in_IN return_NN for_IN the_DT sale_NN of_IN a_DT portion_NN of_IN the_DT potential_JJ future_NN royalty_NN and_CC revenue_NN streams_NNS from_IN DepoDur_NNP ,_, Xatral_NNP OD_NNP ,_, Solaraze_NNP and_CC DepoCyt_NNP ._.
No_DT income_NN was_VBD recognized_VBN under_IN this_DT agreement_NN during_IN 2004_CD 2003_CD :_: 1.1_CD million_CD since_IN all_DT of_IN the_DT income_NN had_VBD been_VBN recognized_VBN as_IN at_IN 31_CD December_NNP 2003_CD ._.
Royalty_NN payments_NNS to_TO Paul_NNP Capital_NNP of_IN 1.3_CD million_CD 2003_CD :_: 1.0_CD million_CD have_VBP been_VBN expensed_VBN during_IN the_DT year_NN ._.
Under_IN the_DT second_JJ transaction_NN Paul_NNP Capital_NNP provided_VBD a_DT further_JJ $_$ 30_CD million_CD during_IN 2002_CD and_CC 2003_CD ,_, in_IN return_NN for_IN the_DT sale_NN of_IN a_DT portion_NN of_IN the_DT potential_JJ future_NN royalty_NN and_CC revenue_NN streams_NNS from_IN nine_CD products_NNS from_IN the_DT Groups_NNS drug_NN pipeline_NN ._.
Income_NN of_IN 1.2_CD million_CD 2003_CD :_: 5.0_CD million_CD was_VBD recognized_VBN as_IN Other_JJ operating_NN income_NN under_IN this_DT agreement_NN on_IN a_DT cost_NN to_TO complete_VB basis_NN ._.
Royalty_NN payments_NNS to_TO Paul_NNP Capital_NNP of_IN 1.7_CD million_CD 2003_CD :_: 2.2_CD million_CD have_VBP been_VBN expensed_VBN during_IN the_DT year_NN ._.
52_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 4_CD Exceptional_JJ items_NNS Exceptional_JJ items_NNS are_VBP categorised_VBN as_IN follows_VBZ :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000_CD Operating_NN exceptional_JJ items_NNS :_: Restructuring_NN costs_NNS 1,208_CD 2,673_CD Provision_NNP for_IN diminution_NN in_IN value_NN of_IN fixed_JJ asset_NN investments_NNS 3,503_CD 1,599_CD Impairment_NN of_IN intellectual_JJ property_NN 2,673_CD Impairment_NN of_IN tangible_JJ fixed_JJ assets_NNS 1,324_CD Settlement_NNP of_IN licensing_NN dispute_NN 1,218_CD 4,711_CD 9,487_CD Non_NNP operating_NN exceptional_JJ items_NNS :_: Profit_NN on_IN disposal_NN of_IN investment_NN 2,021_CD Write_VB off_RP unamortised_JJ issue_NN costs_NNS on_IN exchange_NN of_IN convertible_JJ bonds_NNS 338_CD 3,028_CD 9,487_CD Exceptional_JJ items_NNS include_VBP 1.2_CD million_CD relating_VBG to_TO the_DT reorganisation_NN of_IN some_DT research_NN and_CC development_NN operations_NNS and_CC other_JJ business_NN functions_NNS commenced_VBN during_IN 2003_CD ._.
The_DT reorganisation_NN is_VBZ expected_VBN to_TO be_VB completed_VBN during_IN 2005_CD note_NN 19_CD :_: Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS ._.
A_DT charge_NN of_IN 3.5_CD million_CD was_VBD recorded_VBN for_IN a_DT provision_NN for_IN diminution_NN in_IN value_NN of_IN fixed_JJ asset_NN investments_NNS note_VBP 12_CD :_: Fixed_JJ asset_NN investments_NNS ._.
In_IN addition_NN ,_, 2.0_CD million_CD relates_VBZ to_TO the_DT profit_NN on_IN disposal_NN of_IN the_DT Groups_NNS investment_NN in_IN Transition_NN Therapeutics_NNS note_VBP 12_CD :_: Fixed_JJ asset_NN investments_NNS ._.
A_DT further_JJ 0.3_CD million_CD relates_VBZ to_TO the_DT write_VB off_IN of_IN unamortised_JJ issue_NN costs_NNS on_IN the_DT 2005_CD convertible_JJ bonds_NNS on_IN exchange_NN for_IN 2024_CD bonds_NNS note_VBP 18_CD :_: Convertible_JJ bonds_NNS ._.
The_DT exceptional_JJ items_NNS do_VBP not_RB give_VB rise_VB to_TO a_DT taxation_NN charge_NN or_CC credit_NN ._.
5_CD Operating_NN loss_NN Operating_NN loss_NN is_VBZ stated_VBN after_IN charging_VBG :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000_CD Depreciation_NN of_IN tangible_JJ fixed_JJ assets_NNS owned_VBN assets_NNS 5,549_CD 5,704_CD assets_NNS held_VBN under_IN hire_NN purchase_NN and_CC finance_NN leases_NNS 445_CD 590_CD Amortisation_NNP of_IN intangible_JJ fixed_JJ assets_NNS amortisation_NN of_IN goodwill_NN 4,136_CD 4,072_CD amortisation_NN of_IN intellectual_JJ property_NN 1,980_CD 2,379_CD Amortisation_NNP of_IN associate_JJ goodwill_NN 6_CD Research_NNP and_CC development_NN expenses_NNS current_JJ year_NN expenditure_NN 27,961_CD 30,520_CD amortisation_NN of_IN deferred_VBN expenditure_NN 198_CD 218_CD Operating_NN lease_NN rentals_NNS property_NN rentals_NNS 3,262_CD 3,405_CD hire_NN of_IN plant_NN and_CC machinery_NN 45_CD 86_CD 2004_CD SkyePharma_NNP Annual_JJ Report_NNP 53_CD 5_CD Operating_NN loss_NN continued_VBD Services_NNP provided_VBN by_IN the_DT Groups_NNS auditor_NN and_CC network_NN firms_NNS It_PRP is_VBZ the_DT Groups_NNS policy_NN to_TO employ_VB the_DT auditors_NNS on_IN assignments_NNS additional_JJ to_TO their_PRP$ statutory_JJ audit_NN duties_NNS where_WRB their_PRP$ expertise_NN and_CC experience_NN with_IN the_DT Group_NNP are_VBP important_JJ ,_, principally_RB tax_NN advice_NN and_CC due_JJ diligence_NN reporting_VBG on_IN acquisitions_NNS ,_, or_CC where_WRB they_PRP are_VBP awarded_VBN assignments_NNS on_IN a_DT competitive_JJ basis_NN ._.
During_IN the_DT year_NN the_DT Group_NNP including_VBG its_PRP$ overseas_JJ subsidiaries_NNS obtained_VBD the_DT following_JJ services_NNS from_IN the_DT Groups_NNS auditor_NN at_IN costs_NNS detailed_VBN below_IN :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000_CD Audit_NNP services_NNS statutory_JJ audit_NN 290_CD 326_CD audit_NN related_VBN regulatory_JJ reporting_NN 190_CD 145_CD Further_JJ assurance_NN services_NNS 1,004_CD 227_CD Tax_NNP services_NNS compliance_NN services_NNS 103_CD 228_CD advisory_JJ services_NNS 584_CD 523_CD Other_JJ services_NNS not_RB covered_VBN above_IN 25_CD 2,171_CD 1,474_CD Included_VBN in_IN the_DT analysis_NN above_IN are_VBP Group_NNP audit_NN fees_NNS paid_VBN to_TO the_DT Groups_NNS auditor_NN of_IN 177,000_CD 2003_CD :_: 160,000_CD of_IN which_WDT 14,000_CD 2003_CD :_: 13,000_CD was_VBD paid_VBN in_IN respect_NN of_IN the_DT parent_NN company_NN ._.
Also_RB included_VBN above_IN are_VBP fees_NNS paid_VBN to_TO the_DT Groups_NNS auditor_NN in_IN respect_NN of_IN non-audit_JJ services_NNS in_IN the_DT UK_NNP of_IN 1,141,000_CD 2003_CD :_: 710,000_CD ._.
6_CD Employees_NNS Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000_CD Employment_NNP costs_NNS :_: Wages_NNS and_CC salaries_NNS 19,234_CD 22,511_CD Social_NNP security_NN costs_NNS 2,940_CD 3,441_CD Pension_NN costs_NNS 2,049_CD 1,769_CD 24,223_CD 27,721_CD The_DT average_NN monthly_JJ number_NN of_IN persons_NNS employed_VBN by_IN the_DT Group_NNP including_VBG Executive_NNP Directors_NNS during_IN the_DT year_NN was_VBD as_IN follows_VBZ :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2004_CD 31_CD December_NNP 2003_CD Number_NNP Number_NNP Pharmaceuticals_NNP 438_CD 476_CD Directors_NNS remuneration_NN for_IN the_DT year_NN is_VBZ shown_VBN in_IN the_DT audited_JJ part_NN of_IN the_DT Remuneration_NNP Report_NNP ._.
54_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 7_CD Interest_NN payable_JJ Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000_CD Interest_NN payable_JJ on_IN bank_NN loans_NNS ,_, overdrafts_NNS and_CC other_JJ loans_NNS :_: Repayable_JJ within_IN five_CD years_NNS ,_, not_RB by_IN instalments_NNS 179_CD 93_CD Repayable_JJ within_IN five_CD years_NNS ,_, by_IN instalments_NNS 527_CD 365_CD Repayable_JJ wholly_RB or_CC partly_RB in_IN more_JJR than_IN five_CD years_NNS 26_CD Finance_NNP leases_NNS 9_CD 70_CD Interest_NN on_IN convertible_JJ bonds_NNS 5,069_CD 3,939_CD Write_VB off_RP unamortised_JJ issue_NN costs_NNS on_IN exchange_NN of_IN convertible_JJ bonds_NNS 338_CD 6,122_CD 4,493_CD 8_CD Taxation_NNP Loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN ,_, as_IN shown_VBN in_IN the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN ,_, is_VBZ analyzed_VBN between_IN its_PRP$ component_NN parts_NNS as_IN follows_VBZ :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000_CD UK_NNP 177_CD 821_CD Overseas_JJ 24,225_CD 42,162_CD 24,048_CD 42,983_CD Taxation_NNP charge_NN based_VBN on_IN loss_NN for_IN the_DT year_NN :_: Overseas_NNP taxation_NN 248_CD 240_CD Overseas_JJ taxation_NN relates_VBZ principally_RB to_TO withholding_VBG tax_NN paid_VBN on_IN remittance_NN of_IN royalties_NNS to_TO Switzerland_NNP which_WDT is_VBZ not_RB recoverable_JJ ._.
There_EX was_VBD no_DT deferred_JJ tax_NN component_NN in_IN the_DT tax_NN charge_NN for_IN the_DT years_NNS presented_VBN ._.
The_DT Group_NNP has_VBZ estimated_VBN total_JJ tax_NN losses_NNS available_JJ to_TO be_VB set_VBN off_RP against_IN future_JJ taxable_JJ profits_NNS of_IN 271.1_CD million_CD 31_CD December_NNP 2003_CD :_: 211.3_CD million_CD ._.
These_DT losses_NNS arise_VBP primarily_RB in_IN Switzerland_NNP and_CC the_DT US_NNP ._.
Of_IN the_DT 271.1_CD million_CD of_IN losses_NNS carried_VBD forward_RB ,_, 19.7_CD million_CD expire_VBP in_IN 2005_CD ,_, 76.7_CD million_CD expire_VBP between_IN 2006_CD and_CC 2008_CD ,_, 172.4_CD million_CD expire_VBP from_IN 2009_CD onwards_NNS and_CC 2.3_CD million_CD of_IN losses_NNS may_MD be_VB carried_VBN forward_RB indefinitely_RB ._.
The_DT above_IN charges_NNS reconcile_VBP with_IN the_DT applicable_JJ UK_NNP statutory_JJ corporation_NN tax_NN rate_NN as_IN follows_VBZ :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2004_CD 31_CD December_NNP 2003_CD %_NN %_NN Statutory_NNP UK_NNP Corporation_NNP tax_NN rate_NN 30.0_CD 30.0_CD Tax_NNP rate_NN differences_NNS 17.2_CD 5.9_CD Permanent_JJ differences_NNS 8.2_CD 1.2_CD Tax_NNP losses_NNS not_RB recognized_VBN as_IN deferred_JJ tax_NN assets_NNS 40.0_CD 22.1_CD Other_JJ items_NNS not_RB recognized_VBN as_IN deferred_JJ tax_NN assets_NNS 13.2_CD Effective_JJ tax_NN rate_NN 1.0_CD 0.6_CD 2004_CD SkyePharma_NNP Annual_JJ Report_NNP 55_CD 9_CD Loss_NN per_IN Ordinary_NNP Share_NNP Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000_CD Attributable_JJ loss_NN before_IN exceptional_JJ items_NNS and_CC amortisation_NN 14,948_CD 27,067_CD Exceptional_JJ items_NNS 3,028_CD 9,487_CD Amortisation_NNP 6,320_CD 6,669_CD Basic_JJ and_CC diluted_JJ attributable_JJ loss_NN 24,296_CD 43,223_CD 000_CD 000_CD Basic_JJ and_CC diluted_JJ weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN 615,203_CD 609,855_CD Loss_NN per_IN Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS and_CC amortisation_NN 2.4_CD p_NN 4.4_CD p_NN Exceptional_JJ items_NNS 0.5_CD p_NN 1.6_CD p_NN Amortisation_NNP 1.0_CD p_NN 1.1_CD p_NN Basic_JJ and_CC diluted_JJ loss_NN per_IN Ordinary_NNP Share_NNP 3.9_CD p_NN 7.1_CD p_NN There_EX is_VBZ no_DT difference_NN between_IN basic_JJ and_CC diluted_JJ loss_NN per_IN Ordinary_NNP Share_NNP since_IN in_IN a_DT loss_NN making_VBG year_NN all_DT potential_JJ Ordinary_NNP Shares_NNP are_VBP anti-dilutive_JJ ._.
Shares_NNS held_VBN by_IN the_DT SkyePharma_NNP PLC_NNP General_NNP Employee_NNP Benefit_NNP Trust_NNP have_VBP been_VBN excluded_VBN from_IN the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS ._.
10_CD Intangible_JJ fixed_JJ assets_NNS Intellectual_NNP Development_NNP Goodwill_NNP property_NN costs_NNS Total_JJ Group_NNP 000 000 000 000_CD Cost_NN At_IN 1_CD January_NNP 2004_CD 82,730_CD 36,127_CD 1,712_CD 120,569_CD Exchange_NNP adjustments_NNS 89_CD 19_CD 108_CD Additions_NNS 2,928_CD 2,928_CD At_IN 31_CD December_NNP 2004_CD 82,730_CD 38,966_CD 1,693_CD 123,389_CD Amortisation_NNP At_IN 1_CD January_NNP 2004_CD 14,025_CD 10,436_CD 1,012_CD 25,473_CD Exchange_NNP adjustments_NNS 109_CD 26_CD 83_CD Charge_NNP for_IN the_DT year_NN 4,136_CD 1,980_CD 198_CD 6,314_CD At_IN 31_CD December_NNP 2004_CD 18,161_CD 12,525_CD 1,184_CD 31,870_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2003_CD 68,705_CD 25,691_CD 700_CD 95,096_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2004_CD 64,569_CD 26,441_CD 509_CD 91,519_CD Intellectual_NNP property_NN includes_VBZ 1.2_CD million_CD following_VBG a_DT restructuring_NN of_IN the_DT arrangements_NNS with_IN RDF_NNP existing_VBG at_IN the_DT time_NN of_IN the_DT DepoTech_NNP acquisition_NN in_IN 1999_CD see_VBP note_NN 23_CD :_: Called_VBN up_RP share_NN capital_NN ._.
Tangible_JJ fixed_JJ assets_NNS include_VBP net_JJ book_NN value_NN of_IN 1,311,000_CD 31_CD December_NNP 2003_CD :_: 2,011,000_CD in_IN respect_NN of_IN assets_NNS held_VBN under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN contracts_NNS ._.
This_DT comprises_VBZ 1,221,000_CD 31_CD December_NNP 2003_CD :_: 1,865,000_CD in_IN respect_NN of_IN laboratory_NN equipment_NN and_CC machines_NNS ,_, 12,000_CD 31_CD December_NNP 2003_CD :_: 19,000_CD in_IN respect_NN of_IN office_NN and_CC other_JJ equipment_NN and_CC 78,000_CD 31_CD December_NNP 2003_CD :_: 127,000_CD in_IN respect_NN of_IN motor_NN vehicles_NNS ._.
Office_NNP and_CC Land_NNP and_CC other_JJ buildings_NNS equipment_NN Total_JJ Company_NN 000 000 000_CD Cost_NN At_IN 1_CD January_NNP 2004 108 349 457_CD Additions_NNS 2_CD 2_CD At_IN 31_CD December_NNP 2004 108 351 459_CD Depreciation_NNP At_IN 1_CD January_NNP 2004 87 266 353_CD Charge_NNP for_IN the_DT year_NN 11_CD 33_CD 44_CD At_IN 31_CD December_NNP 2004 98 299 397_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2003_CD 21_CD 83_CD 104_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2004_CD 10_CD 52_CD 62_CD 2004_CD SkyePharma_NNP Annual_JJ Report_NNP 57_CD 12_CD Fixed_VBN asset_NN investments_NNS a_DT Group_NNP Investments_NNPS Unlisted_NNP in_IN associates_NNS investments_NNS Total_JJ 000 000 000_CD Cost_NN At_IN 1_CD January_NNP 2004_CD as_IN restated_VBN 22,024_CD 22,024_CD Reclassification_NN of_IN associate_JJ 14,217_CD 14,217_CD Additions_NNPS 125_CD 2,103_CD 2,228_CD Disposals_NNS 629_CD 629_CD Share_NN of_IN loss_NN in_IN associate_NN and_CC amortisation_NN of_IN associate_JJ goodwill_NN 16_CD 16_CD Provision_NNP for_IN diminution_NN in_IN value_NN note_NN 4_CD 3,503_CD 3,503_CD At_IN 31_CD December_NNP 2004_CD 14,326_CD 5,778_CD 20,104_CD Shares_NNS held_VBN by_IN the_DT ESOP_NNP trust_NN have_VBP been_VBN reclassified_VBN from_IN fixed_VBN asset_NN investments_NNS in_IN own_JJ shares_NNS to_TO reserves_NNS in_IN accordance_NN with_IN UITF_NNP 38_CD ._.
The_DT restatement_NN has_VBZ resulted_VBN in_IN a_DT reduction_NN of_IN the_DT opening_NN balance_NN of_IN 1,395,000_CD ._.
Associates_NNPS Astralis_NNP Limited_NNP Astralis_NNP Limited_NNP is_VBZ an_DT emerging_VBG biotechnology_NN company_NN based_VBN and_CC incorporated_VBN in_IN the_DT US_NNP ,_, and_CC engaged_VBD primarily_RB in_IN the_DT research_NN and_CC development_NN of_IN novel_NN treatments_NNS for_IN immune_JJ system_NN disorders_NNS and_CC skin_NN diseases_NNS ._.
The_DT company_NN is_VBZ currently_RB developing_VBG two_CD products_NNS ._.
Its_PRP$ primary_JJ product_NN ,_, Psoraxine_NNP ,_, is_VBZ an_DT innovative_JJ vaccine_NN under_IN development_NN for_IN the_DT treatment_NN of_IN psoriasis_NN ._.
The_DT companys_NNS second_JJ product_NN is_VBZ for_IN the_DT treatment_NN of_IN leishmaniasis_NN ._.
In_IN January_NNP 2004_CD SkyePharma_NNP converted_VBD all_DT of_IN its_PRP$ 2_CD million_CD series_NN A_DT convertible_JJ preferred_JJ shares_NNS into_IN 25_CD million_CD common_JJ shares_NNS ,_, 12.5_CD million_CD of_IN these_DT being_VBG held_VBN in_IN escrow_NN ._.
The_DT resulting_VBG holding_VBG represented_VBN approximately_RB 35.7_CD %_NN of_IN the_DT common_JJ shares_NNS ._.
The_DT investment_NN was_VBD not_RB regarded_VBN as_IN an_DT associated_VBN undertaking_NN as_IN the_DT Directors_NNS concluded_VBD that_IN the_DT Group_NNP did_VBD not_RB exert_VB significant_JJ influence_NN ._.
In_IN December_NNP 2004_CD SkyePharma_NNP signed_VBD conditional_JJ stock_NN purchase_NN and_CC assignment_NN agreements_NNS with_IN two_CD former_JJ Astralis_NNP Directors_NNS to_TO acquire_VB 11,160,000_CD common_JJ shares_NNS and_CC appoint_VB a_DT further_JJ two_CD Directors_NNS representing_VBG SkyePharma_NNP to_TO the_DT Astralis_NNP Board_NNP ._.
The_DT Group_NNP also_RB acquired_VBD 33,900_CD common_JJ shares_NNS of_IN Astralis_NNP for_IN approximately_RB 12,000_CD ._.
As_IN at_IN 31_CD December_NNP 2004_CD the_DT total_JJ SkyePharma_NNP holding_NN was_VBD 25,233,900_CD common_JJ shares_NNS and_CC 20,000_CD warrants_NNS ,_, representing_VBG approximately_RB 34.5_CD %_NN of_IN the_DT common_JJ shares_NNS ._.
As_IN a_DT result_NN of_IN these_DT events_NNS the_DT investment_NN has_VBZ been_VBN treated_VBN as_IN an_DT associated_VBN undertaking_NN from_IN December_NNP 2004_CD ._.
Goodwill_NN of_IN 13.7_CD million_CD arose_VBD on_IN the_DT acquisition_NN as_IN shown_VBN in_IN note_NN 28_CD :_: Acquisitions_NNS ._.
SkyePharmas_NNP share_NN of_IN the_DT loss_NN of_IN Astralis_NNP for_IN the_DT period_NN was_VBD 10,000_CD and_CC the_DT amortisation_NN of_IN the_DT associate_JJ goodwill_NN was_VBD 6,000_CD ._.
Astralis_NNP is_VBZ audited_VBN by_IN a_DT firm_NN other_JJ than_IN LLP_NNP ._.
In_IN March_NNP 2005_CD Astralis_NNP announced_VBD that_IN the_DT phase_NN II_NNP study_NN of_IN its_PRP$ product_NN Psoraxine_NNP did_VBD not_RB meet_VB the_DT primary_JJ study_NN endpoint_NN upon_IN completion_NN of_IN the_DT treatment_NN phase_NN of_IN the_DT study_NN ._.
The_DT Company_NN is_VBZ currently_RB working_VBG with_IN Astralis_NNP to_TO investigate_VB and_CC resolve_VB the_DT possible_JJ reasons_NNS for_IN the_DT result_NN ._.
Pending_VBG the_DT outcome_NN of_IN these_DT investigations_NNS the_DT Directors_NNS have_VBP no_DT basis_NN to_TO believe_VB that_IN the_DT underlying_JJ value_NN of_IN the_DT business_NN has_VBZ been_VBN affected_VBN ._.
In_IN March_NNP 2005_CD SkyePharma_NNP acquired_VBD the_DT 11,160,000_CD common_JJ shares_NNS from_IN two_CD former_JJ Astralis_NNP Directors_NNS ._.
Unlisted_JJ investments_NNS Micap_NNP plc_NN Micap_NNP plc_NN is_VBZ a_DT UK_NNP science-based_JJ technology_NN company_NN traded_VBD on_IN the_DT Alternative_NNP Investment_NNP Market_NNP ._.
As_IN at_IN 31_CD December_NNP 2004_CD the_DT total_JJ SkyePharma_NNP holding_NN was_VBD 5,238,334_CD ordinary_JJ shares_NNS and_CC 1,830,000_CD convertible_JJ shares_NNS ,_, representing_VBG approximately_RB 18.2_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN ._.
The_DT ordinary_JJ shares_NNS and_CC convertible_JJ shares_NNS are_VBP recorded_VBN at_IN a_DT cost_NN of_IN 2.1_CD million_CD ._.
Transition_NN Therapeutics_NNPS Inc_NNP In_IN May_NNP 2004_CD SkyePharma_NNP disposed_VBD of_IN its_PRP$ investment_NN in_IN Transition_NN Therapeutics_NNS for_IN 2.6_CD million_CD ,_, resulting_VBG in_IN a_DT profit_NN on_IN disposal_NN of_IN 2.0_CD million_CD note_NN 4_CD :_: Exceptional_JJ items_NNS ._.
Vectura_NNP Group_NNP plc_NN Vectura_NNP is_VBZ a_DT UK_NNP emerging_VBG pharmaceutical_JJ company_NN traded_VBN on_IN the_DT Alternative_NNP Investment_NNP Market_NNP from_IN July_NNP 2004_CD ._.
Vectura_NNP is_VBZ developing_VBG a_DT range_NN of_IN inhaled_JJ drugs_NNS for_IN the_DT treatment_NN of_IN lung_NN diseases_NNS and_CC conditions_NNS where_WRB delivery_NN via_IN the_DT lungs_NNS can_MD provide_VB significant_JJ benefits_NNS ,_, such_JJ as_IN rapid_JJ onset_NN of_IN action_NN ,_, improved_VBD efficacy_NN and_CC improved_VBD tolerability_NN compared_VBN with_IN current_JJ therapies_NNS ._.
During_IN the_DT year_NN the_DT Group_NNP acquired_VBD 3.2_CD million_CD ordinary_JJ shares_NNS ,_, representing_VBG approximately_RB 3.0_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN ._.
The_DT ordinary_JJ shares_NNS are_VBP recorded_VBN at_IN a_DT cost_NN of_IN 2.0_CD million_CD ._.
58_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 12_CD Fixed_VBN asset_NN investments_NNS continued_VBD Vital_NNP Living_VBG Inc_NNP Vital_NNP Living_VBG primarily_RB develops_VBZ and_CC markets_VBZ evidence-based_JJ nutriceuticals_NNS ._.
These_DT are_VBP developed_VBN for_IN incorporation_NN by_IN physicians_NNS into_IN a_DT standard_JJ physician_NN patient_NN program_NN ,_, supported_VBN by_IN a_DT specially_RB designed_VBN compliance_NN regimen_NN ._.
Vital_JJ Living_VBG is_VBZ based_VBN in_IN the_DT US_NNP ._.
During_IN the_DT year_NN the_DT Group_NNP received_VBD 687,629_CD Vital_JJ Living_VBG common_JJ shares_NNS with_IN a_DT value_NN of_IN 42,000_CD $_$ 80,000_CD in_IN lieu_NN of_IN interest_NN due_JJ on_IN the_DT 12_CD %_NN senior_JJ secured_VBN convertible_JJ notes_NNS ._.
The_DT shares_NNS do_VBP not_RB represent_VB qualifying_VBG consideration_NN and_CC have_VBP therefore_RB been_VBN recorded_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
As_IN at_IN 31_CD December_NNP 2004_CD the_DT total_JJ SkyePharma_NNP holding_NN was_VBD 14,892,177_CD common_JJ shares_NNS ,_, 1_CD million_CD series_NN D_NNP convertible_JJ preferred_JJ shares_NNS ,_, $_$ 1_CD million_CD 12_CD %_NN senior_JJ secured_VBN convertible_JJ notes_NNS due_JJ 2008_CD and_CC 1_CD million_CD warrants_NNS expiring_VBG 2008_CD ,_, representing_VBG approximately_RB 15.0_CD %_NN of_IN the_DT common_JJ shares_NNS ._.
A_DT provision_NN for_IN diminution_NN in_IN value_NN of_IN 3.5_CD million_CD has_VBZ been_VBN made_VBN such_JJ that_IN the_DT investment_NN was_VBD recorded_VBN at_IN 1.7_CD million_CD as_IN at_IN 31_CD December_NNP 2004_CD based_VBN on_IN the_DT year_NN end_NN share_NN price_NN ._.
Cade_NNP Struktur_NNP Corp_NNP Cade_NNP Struktur_NNP was_VBD formerly_RB a_DT drug_NN delivery_NN company_NN engaged_VBD in_IN research_NN and_CC development_NN and_CC worldwide_JJ commercialisation_NN of_IN pharmaceutical_JJ formulations_NNS ._.
The_DT current_JJ business_NN is_VBZ the_DT development_NN ,_, financing_NN and_CC completion_NN of_IN industrial_JJ and_CC infrastructure_NN projects_NNS in_IN Europe_NNP ._.
As_IN at_IN 31_CD December_NNP 2004_CD ,_, the_DT total_JJ SkyePharma_NNP holding_NN of_IN Cade_NNP Struktur_NNP ,_, a_DT Canadian_JJ company_NN ,_, was_VBD 869,086_CD shares_NNS ,_, representing_VBG approximately_RB 10.1_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN ._.
The_DT shares_NNS were_VBD originally_RB acquired_VBN consequent_JJ upon_IN the_DT acquisition_NN of_IN the_DT assets_NNS of_IN Hyal_NNP Pharmaceutical_NNP Corp._NNP ._.
SkyePharma_NNP has_VBZ not_RB attributed_VBN a_DT value_NN to_TO these_DT shares_NNS and_CC they_PRP have_VBP been_VBN recorded_VBN at_IN zero_CD cost_NN ._.
b_NN Company_NN Shares_NNS in_IN Loans_NNS to_TO Group_NNP Group_NNP Investments_NNPS Unlisted_NNP undertakings_NNS undertakings_NNS in_IN associates_NNS investments_NNS Total_JJ 000 000 000 000_CD 000_CD At_IN 1_CD January_NNP 2004_CD as_IN restated_VBN 209,882_CD 194,318_CD 16,332_CD 420,532_CD Reclassification_NN of_IN associate_JJ 14,217_CD 14,217_CD Additions_NNPS 49,000_CD 125_CD 2,047_CD 51,172_CD Write_VB down_RP 23,074_CD 6,000_CD 29,074_CD Redemption_NN of_IN preference_NN shares_NNS 23,335_CD 23,335_CD At_IN 31_CD December_NNP 2004_CD 163,473_CD 237,318_CD 14,342_CD 4,162_CD 419,295_CD Shares_NNS held_VBN by_IN the_DT ESOP_NNP trust_NN have_VBP been_VBN reclassified_VBN from_IN fixed_VBN asset_NN investments_NNS in_IN own_JJ shares_NNS to_TO reserves_NNS in_IN accordance_NN with_IN UITF_NNP 38_CD ._.
The_DT Company_NN has_VBZ written_VBN down_RP its_PRP$ investments_NNS in_IN SkyePharma_NNP Canada_NNP Inc_NNP and_CC SkyePharma_NNP AB_NNP to_TO Nil_NNP as_IN a_DT result_NN of_IN the_DT reorganisation_NN ._.
13_CD Stock_NNP Group_NNP Group_NNP 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000_CD Raw_NNP materials_NNS and_CC consumables_NNS 1,216_CD 981_CD Work_NN in_IN progress_NN 221_CD 266_CD Finished_VBN goods_NNS 94_CD 73_CD 1,531_CD 1,320_CD The_DT replacement_NN cost_NN of_IN stock_NN is_VBZ not_RB materially_RB different_JJ from_IN original_JJ cost_NN ._.
2004_CD SkyePharma_NNP Annual_JJ Report_NNP 59_CD 14_CD Debtors_NNP Group_NNP Group_NNP Company_NNP Company_NNP 31_CD December_NNP 2004_CD 31_CD December_NNP 2003_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000 000_CD 000_CD Trade_NNP debtors_NNS 3,486_CD 2,800_CD Amounts_NNS owed_VBN by_IN subsidiary_NN undertakings_NNS 5,164_CD 5,481_CD Prepayments_NNS and_CC accrued_VBN income_NN 12,412_CD 9,485_CD 223_CD 728_CD Interest_NN receivable_NN 407 396 136_CD Other_JJ debtors_NNS Due_JJ within_IN one_CD year_NN 2,788_CD 2,151_CD 1,109_CD 103_CD Due_JJ after_IN more_JJR than_IN one_CD year_NN 770_CD 802_CD 19,863_CD 15,634_CD 6,496_CD 6,448_CD 15_CD Current_JJ Asset_NNP Investments_NNP Current_JJ asset_NN investments_NNS comprise_VBP 5_CD %_NN convertible_JJ loan_NN notes_NNS due_JJ at_IN par_NN in_IN June_NNP 2007_CD ._.
The_DT notes_NNS were_VBD received_VBN from_IN GeneMedix_NNP plc_NN in_IN 2002_CD as_IN an_DT initial_JJ payment_NN under_IN an_DT agreement_NN to_TO jointly_RB develop_VB an_DT extended_JJ release_NN formulation_NN of_IN Interferon_NNP alpha-2b_JJ using_VBG SkyePharmas_NNP DepoFoam_NNP technology_NN ._.
The_DT notes_NNS are_VBP convertible_JJ at_IN any_DT time_NN ,_, at_IN SkyePharmas_NNP option_NN ,_, into_IN between_IN approximately_RB 8.3_CD million_CD and_CC 11.2_CD million_CD GeneMedix_NNP ordinary_JJ shares_NNS ._.
There_EX are_VBP no_DT restrictions_NNS or_CC a_DT lock-up_JJ period_NN on_IN conversion_NN of_IN the_DT notes_NNS ._.
GeneMedix_NNP can_MD elect_VB to_TO redeem_VB in_IN cash_NN some_DT or_CC all_DT of_IN the_DT notes_NNS on_IN conversion_NN ._.
The_DT notes_NNS have_VBP been_VBN recorded_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN assuming_VBG conversion_NN ._.
16_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN Group_NNP Group_NNP Company_NNP Company_NNP 31_CD December_NNP 2004_CD 31_CD December_NNP 2003_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000 000_CD 000_CD Bank_NNP overdrafts_NNS 1,198_CD Bank_NNP loans_NNS 3,526_CD 2,342_CD 1,923_CD 761_CD Current_JJ portion_NN of_IN secured_JJ mortgage_NN note_NN 17 275 271_CD Convertible_JJ bonds_NNS due_JJ June_NNP 2005_CD 9,774_CD 9,774_CD Chiron_NNP promissory_JJ note_NN 559_CD Obligations_NNS under_IN hire_NN purchase_NN and_CC finance_NN leases_NNS 75_CD 160_CD Trade_NNP creditors_NNS 6,740_CD 5,915_CD 571_CD 337_CD Amounts_NNS owed_VBN to_TO subsidiary_NN undertakings_NNS 72,752_CD 9,639_CD Corporation_NNP tax_NN 3_CD 3_LS -_: Other_JJ taxation_NN and_CC social_JJ security_NN costs_NNS 1,195_CD 1,628_CD 86_CD 221_CD Deferred_JJ income_NN 14,291_CD 12,926_CD Accruals_NNPS 12,672_CD 14,318_CD 2,495_CD 3,574_CD 48,551_CD 39,320_CD 87,601_CD 14,532_CD At_IN 31_CD December_NNP 2004_CD the_DT Group_NNP had_VBD an_DT overdraft_NN facility_NN of_IN 1.4_CD million_CD CHF_NNP 3_CD million_CD with_IN the_DT Basellandschaftliche_NNP Kantonalbank_NNP secured_VBN on_IN the_DT assets_NNS of_IN Jago_NNP ._.
At_IN 31_CD December_NNP 2004_CD bank_NN loans_NNS include_VBP two_CD amounts_NNS due_JJ to_TO the_DT Basellandschaftliche_NNP Kantonalbank_NNP of_IN 0.9_CD million_CD CHF_NNP 2_CD million_CD and_CC 0.7_CD million_CD CHF_NNP 1.5_CD million_CD ._.
Both_DT loans_NNS are_VBP renewable_JJ annually_RB and_CC bear_VB interest_NN at_IN 6.5_CD %_NN and_CC 6.0_CD %_NN respectively_RB ._.
Both_DT loans_NNS are_VBP secured_VBN on_IN the_DT assets_NNS of_IN Jago_NNP and_CC the_DT 0.7_CD million_CD CHF_NNP 1.5_CD million_CD loan_NN is_VBZ guaranteed_VBN by_IN SkyePharma_NNP PLC._NNP ._.
The_DT Group_NNP had_VBD a_DT loan_NN as_IN at_IN 31_CD December_NNP 2004_CD with_IN GE_NNP Capital_NNP Corp_NNP of_IN 1.9_CD million_CD $_$ 3.7_CD million_CD ._.
The_DT loan_NN is_VBZ secured_VBN by_IN certain_JJ assets_NNS of_IN SkyePharma_NNP Inc_NNP ,_, SkyePharma_NNP US_NNP Inc_NNP and_CC SkyePharma_NNP PLC._NNP ._.
The_DT loan_NN bears_VBZ interest_NN at_IN 8.0_CD %_NN and_CC is_VBZ repayable_JJ by_IN instalments_NNS until_IN between_IN June_NNP 2005_CD and_CC September_NNP 2007_CD ._.
60_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 17_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN Group_NNP Group_NNP Company_NNP Company_NNP 31_CD December_NNP 2004_CD 31_CD December_NNP 2003_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000 000_CD 000_CD Bank_NNP loans_NNS 1,923_CD 1,923_CD Secured_JJ mortgage_NN 7,100_CD 7,272_CD Convertible_JJ bonds_NNS due_JJ June_NNP 2005_CD 58,791_CD 58,791_CD Convertible_JJ bonds_NNS due_JJ May_NNP 2024_CD 66,478_CD Obligations_NNS under_IN hire_NN purchase_NN and_CC finance_NN leases_NNS 60_CD 206_CD Deferred_JJ income_NN 250_CD 2,948_CD Accruals_NNP 3,302_CD 3,459_CD 77,190_CD 74,599_CD 60,714_CD Bank_NNP and_CC other_JJ loans_NNS are_VBP repayable_JJ as_IN follows_VBZ :_: Between_IN one_CD and_CC two_CD years_NNS 275_CD 1,171_CD 900_CD Between_IN two_CD and_CC three_CD years_NNS 275_CD 1,247_CD 977_CD Between_IN three_CD and_CC four_CD years_NNS 275_CD 318_CD 46_CD Between_IN four_CD and_CC five_CD years_NNS 275_CD 271_CD After_IN five_CD years_NNS 6,000_CD 6,188_CD 7,100_CD 9,195_CD 1,923_CD Obligations_NNS under_IN hire_NN purchase_NN and_CC finance_NN leases_NNS are_VBP repayable_JJ as_IN follows_VBZ :_: Between_IN one_CD and_CC two_CD years_NNS 40_CD 91_CD Between_IN two_CD and_CC three_CD years_NNS 20_CD 96_CD Between_IN three_CD and_CC four_CD years_NNS 19_CD 60_CD 206_CD At_IN 31_CD December_NNP 2004_CD ,_, the_DT Group_NNP had_VBD a_DT property_NN mortgage_NN facility_NN with_IN the_DT Basellandschaftliche_NNP Kantonalbank_NNP of_IN 7.4_CD million_CD CHF_NNP 16.1_CD million_CD of_IN which_WDT 0.3_CD million_CD CHF_NNP 0.6_CD million_CD is_VBZ shown_VBN within_IN current_JJ liabilities_NNS ._.
The_DT mortgage_NN is_VBZ in_IN two_CD tranches_NNS ,_, both_DT secured_VBN by_IN the_DT assets_NNS of_IN Jago_NNP ._.
The_DT first_JJ tranche_NN of_IN 3.0_CD million_CD CHF_NNP 6.6_CD million_CD bears_NNS interest_NN at_IN 2.75_CD %_NN and_CC is_VBZ repayable_JJ by_IN instalments_NNS over_IN 21_CD years_NNS semi-annually_RB ._.
The_DT second_JJ tranche_NN of_IN 4.4_CD million_CD CHF_NNP 9.5_CD million_CD bears_NNS interest_NN at_IN 2.75_CD %_NN and_CC is_VBZ repayable_JJ by_IN instalments_NNS over_IN 51_CD years_NNS ._.
Obligations_NNS under_IN hire_NN purchase_NN and_CC finance_NN leases_NNS are_VBP secured_VBN upon_IN the_DT assets_NNS to_TO which_WDT they_PRP relate_VBP and_CC as_RB at_IN 31_CD December_NNP 2004_CD 0.1_CD million_CD SKR_NNP 0.9_CD million_CD is_VBZ guaranteed_VBN by_IN SkyePharma_NNP PLC._NNP ._.
18_CD Convertible_JJ bonds_NNS In_IN 2000_CD ,_, the_DT Company_NN issued_VBN 59.4_CD million_CD 6_CD %_NN convertible_JJ bonds_NNS due_JJ June_NNP 2005_CD ._.
The_DT bonds_NNS are_VBP convertible_JJ at_IN the_DT option_NN of_IN the_DT holder_NN into_IN Ordinary_NNP Shares_NNP at_IN a_DT conversion_NN price_NN of_IN 83_CD pence_NN ._.
In_IN April_NNP 2004_CD ,_, the_DT Group_NNP issued_VBD 20_CD million_CD 6_CD %_NN convertible_JJ bonds_NNS ,_, with_IN a_DT first_JJ right_NN of_IN conversion_NN after_IN five_CD years_NNS by_IN the_DT holder_NN of_IN the_DT bonds_NNS ,_, and_CC a_DT final_JJ maturity_NN of_IN May_NNP 2024_CD ._.
The_DT bonds_NNS are_VBP convertible_JJ at_IN the_DT option_NN of_IN the_DT holder_NN into_IN Ordinary_NNP Shares_NNP at_IN a_DT conversion_NN price_NN of_IN 1.00_CD ._.
In_IN July_NNP 2004_CD the_DT Group_NNP exchanged_VBD 49.6_CD million_CD of_IN the_DT convertible_JJ bonds_NNS due_JJ 2005_CD for_IN bonds_NNS due_JJ 2024_CD in_IN the_DT same_JJ amount_NN ,_, leaving_VBG 9.8_CD million_CD 2005_CD bonds_NNS outstanding_JJ ._.
No_DT gain_NN or_CC loss_NN arose_VBD on_IN the_DT exchange_NN ,_, however_RB unamortised_JJ issue_NN costs_NNS of_IN 0.3_CD million_CD were_VBD written_VBN off_RP note_NN 4_CD :_: Exceptional_JJ items_NNS ._.
In_IN September_NNP 2004_CD the_DT 49.6_CD million_CD 2024_CD convertible_JJ bonds_NNS were_VBD consolidated_VBN to_TO form_VB a_DT single_JJ series_NN with_IN the_DT 20_CD million_CD 2024_JJ bonds_NNS issued_VBN in_IN May_NNP 2004_CD ._.
As_IN a_DT result_NN of_IN these_DT transactions_NNS there_EX are_VBP 69.6_CD million_CD convertible_JJ bonds_NNS due_JJ May_NNP 2024_CD issued_VBN by_IN SkyePharma_NNP Jersey_NNP Limited_NNP and_CC 9.8_CD million_CD convertible_JJ bonds_NNS due_JJ June_NNP 2005_CD issued_VBN by_IN the_DT Company_NN outstanding_JJ as_IN at_IN 31_CD December_NNP 2004_CD ._.
2004_CD SkyePharma_NNP Annual_JJ Report_NNP 61_CD 19_CD Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS National_NNP Restructuring_NNP Pension_NNP Insurance_NNP Total_NNP Group_NNP 000 000 000 000_CD At_IN 1_CD January_NNP 2004_CD 1,829_CD 285_CD 7_CD 2,121_CD Exchange_NNP adjustments_NNS 23_CD 6_CD 1_CD 18_CD Charge_NNP in_IN the_DT year_NN 1,208_CD 125_CD 7_CD 1,340_CD Utilised_NNP 2,732_CD 2,732_CD At_IN 31_CD December_NNP 2004 282 416_CD 13_CD 711_CD Restructuring_NN provision_NN The_DT restructuring_NN provision_NN relates_VBZ to_TO the_DT reorganisation_NN of_IN research_NN and_CC development_NN operations_NNS and_CC other_JJ business_NN functions_NNS involving_VBG reductions_NNS in_IN staff_NN at_IN most_JJS sites_NNS note_VBP 4_CD :_: Exceptional_JJ items_NNS ._.
The_DT remaining_VBG provision_NN of_IN approximately_RB 0.3_CD million_CD is_VBZ expected_VBN to_TO be_VB fully_RB utilised_VBN in_IN 2005_CD ._.
Pension_NNP provision_NN The_DT pension_NN provision_NN relates_VBZ to_TO the_DT retirement_NN commitments_NNS under_IN a_DT defined_VBN benefit_NN scheme_NN for_IN SkyePharma_NNP Production_NNP SAS_NNP employees_NNS note_VBP 27_CD :_: Pension_NNP Arrangements_NNP ._.
National_NNP Insurance_NNP provision_NN A_DT balance_NN sheet_NN provision_NN of_IN 13,000_CD 31_CD December_NNP 2003_CD :_: 7,000_CD has_VBZ been_VBN recognized_VBN in_IN accordance_NN with_IN UITF_NNP 25_CD :_: National_NNP Insurance_NNP contributions_NNS on_IN share_NN option_NN gains_NNS ._.
20_CD Deferred_JJ taxation_NN Group_NNP full_JJ potential_JJ Company_NN full_JJ potential_JJ 31_CD December_NNP 2004_CD 31_CD December_NNP 2003_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000 000_CD 000_CD Accelerated_VBN capital_NN allowances_NNS 5,680_CD 8,655_CD 54_CD 19_CD Other_JJ timing_NN differences_NNS 5,772_CD 8,485_CD 18_CD UK_NNP tax_NN benefits_NNS from_IN losses_NNS carried_VBD forward_RB 689_CD 2,063_CD 689_CD 2,063_CD Overseas_JJ tax_NN benefits_NNS from_IN losses_NNS carried_VBD forward_RB 48,974_CD 36,607_CD Potential_JJ deferred_JJ tax_NN asset_NN 61,115_CD 55,810_CD 743_CD 2,100_CD No_DT deferred_VBN tax_NN asset_NN is_VBZ recognized_VBN ,_, given_VBN the_DT uncertainty_NN of_IN the_DT recoverability_NN of_IN the_DT Groups_NNS tax_NN losses_NNS carried_VBD forward_RB ._.
21_CD Contingent_JJ liabilities_NNS and_CC guarantees_NNS At_IN 31_CD December_NNP 2004_CD the_DT Company_NN had_VBD provided_VBN guarantees_NNS on_IN various_JJ bank_NN borrowings_NNS of_IN its_PRP$ subsidiaries_NNS as_IN set_VBN out_RP in_IN note_NN 16_CD :_: Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN and_CC note_NN 17_CD :_: Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN ._.
In_IN common_JJ with_IN most_JJS business_NN enterprises_NNS ,_, Group_NNP companies_NNS are_VBP subject_JJ to_TO a_DT number_NN of_IN claims_NNS from_IN third_JJ parties_NNS ,_, the_DT outcome_NN of_IN which_WDT can_MD not_RB at_IN present_JJ be_VB determined_VBN but_CC which_WDT are_VBP not_RB considered_VBN to_TO be_VB material_NN in_IN the_DT context_NN of_IN these_DT financial_JJ statements_NNS ._.
Provisions_NNS have_VBP been_VBN made_VBN in_IN these_DT financial_JJ statements_NNS for_IN any_DT liabilities_NNS which_WDT are_VBP expected_VBN to_TO materialise_VB from_IN such_JJ claims_NNS ._.
62_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 22_CD Commitments_NNP Group_NNP Group_NNP Company_NNP Company_NNP 31_CD December_NNP 2004_CD 31_CD December_NNP 2003_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000 000_CD 000_CD Commitments_NNS under_IN operating_VBG leases_NNS to_TO pay_VB rentals_NNS for_IN the_DT next_JJ year_NN Operating_VBG leases_NNS on_IN land_NN and_CC buildings_NNS which_WDT expire_VBP :_: In_IN one_CD year_NN or_CC less_JJR 583_CD 583_CD In_IN two_CD to_TO five_CD years_NNS 583_CD 583_CD In_IN five_CD years_NNS or_CC more_JJR 2,454_CD 2,832_CD 3,037_CD 3,415_CD 583_CD 583_CD Other_JJ operating_NN leases_NNS which_WDT expire_VBP :_: In_IN one_CD year_NN or_CC less_JJR 3_CD 7_CD 3_CD 7_CD In_IN two_CD to_TO five_CD years_NNS 32_CD 38_CD 9_CD 12_CD 35_CD 45_CD 12_CD 19_CD In_IN addition_NN the_DT Group_NNP has_VBZ committed_VBN to_TO undertake_VB certain_JJ clinical_JJ trials_NNS on_IN behalf_NN of_IN its_PRP$ partners_NNS under_IN development_NN and_CC licensing_NN agreements_NNS ._.
The_DT Group_NNP is_VBZ committed_VBN to_TO make_VB certain_JJ payments_NNS to_TO third_JJ parties_NNS contingent_JJ upon_IN future_JJ events_NNS such_JJ as_IN the_DT approval_NN and_CC launch_NN of_IN products_NNS ._.
23_CD Called_VBN up_RP share_NN capital_NN Equity_NN share_NN capital_NN 31_CD December_NNP 2004_CD 31_CD December_NNP 2003_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2003_CD Number_NNP of_IN shares_NNS Number_NNP of_IN shares_NNS 000_CD 000_CD Authorised_NNP Ordinary_NNP Shares_NNP of_IN 10p_CD each_DT 1,102,000,000_CD 1,102,000,000_CD 110,200_CD 110,200_CD Ordinary_NNP Shares_NNP of_IN Nominal_NNP 10p_CD each_DT Value_NN Number_NN 000_CD Allotted_NNP ,_, called_VBD up_RP and_CC fully_RB paid_VBN At_IN 1_CD January_NNP 2003_CD 613,458,067_CD 61,346_CD Exercise_NN of_IN share_NN options_NNS 1,521,662_CD 152_CD Issue_NN of_IN shares_NNS in_IN respect_NN of_IN RTP_NNP Pharma_NNP Inc._NNP 3,690,211_CD 369_CD At_IN 31_CD December_NNP 2003_CD 618,669,940_CD 61,867_CD Exercise_NN of_IN share_NN options_NNS 478,803_CD 48_CD Issue_NN of_IN shares_NNS to_TO Research_NNP Development_NNP Foundation_NNP RDF_NNP 3,250,000_CD 325_CD At_IN 31_CD December_NNP 2004_CD 622,398,743_CD 62,240_CD During_IN the_DT year_NN the_DT Group_NNP issued_VBD 3,250,000_CD Ordinary_NNP Shares_NNP to_TO RDF_NNP at_IN 57.5_CD pence_NN as_IN a_DT result_NN of_IN a_DT restructuring_NN of_IN the_DT arrangements_NNS with_IN RDF_NNP existing_VBG at_IN the_DT time_NN of_IN the_DT DepoTech_NNP acquisition_NN in_IN 1999_CD ._.
The_DT cash_NN consideration_NN received_VBN on_IN the_DT issue_NN of_IN Ordinary_NNP Shares_NNP on_IN the_DT exercise_NN of_IN share_NN options_NNS during_IN the_DT year_NN amounted_VBD to_TO 261,000_CD 2003_CD :_: 1,437,000_CD ._.
Non-equity_JJ share_NN capital_NN Deferred_VBN B_NNP Shares_NNP of_IN Nominal_NNP 10p_CD each_DT value_NN Number_NN 000_CD Authorised_NNP and_CC called_VBN up_RP At_IN 1_CD January_NNP 2004_CD and_CC 31_CD December_NNP 2004_CD 12,000,000_CD 1,200_CD 2004_CD SkyePharma_NNP Annual_JJ Report_NNP 63_CD 23_CD Called_VBN up_RP share_NN capital_NN continued_VBD In_IN July_NNP 2000_CD ,_, 12_CD million_CD Deferred_NNP A_NNP and_CC 12_CD million_CD Deferred_NNP B_NNP Shares_NNP were_VBD issued_VBN to_TO Dr_NNP Gonella_NNP ,_, the_DT vendor_NN of_IN Jago_NNP ,_, under_IN a_DT settlement_NN agreement_NN that_WDT established_VBD the_DT full_JJ and_CC final_JJ settlement_NN of_IN the_DT deferred_JJ consideration_NN payable_JJ on_IN the_DT acquisition_NN of_IN Jago_NNP ._.
The_DT holders_NNS of_IN Deferred_NNP A_NNP and_CC B_NNP Shares_NNP have_VBP no_DT rights_NNS to_TO participate_VB in_IN the_DT profits_NNS of_IN the_DT Company_NN ,_, no_DT voting_NN rights_NNS and_CC on_IN a_DT winding_VBG up_RP or_CC other_JJ return_NN of_IN capital_NN only_RB receive_VB the_DT nominal_JJ value_NN of_IN their_PRP$ shares_NNS if_IN the_DT holders_NNS of_IN Ordinary_NNP Shares_NNP in_IN the_DT capital_NN of_IN the_DT Company_NN have_VBP received_VBN the_DT sum_NN of_IN 1_CD million_CD per_IN Ordinary_NNP Share_NNP and_CC ,_, as_IN such_JJ ,_, are_VBP classified_VBN as_IN non-equity_JJ shares_NNS ._.
Under_IN the_DT terms_NNS of_IN the_DT settlement_NN agreement_NN ,_, following_VBG the_DT US_NNP launch_NN and_CC first_JJ commercial_JJ sale_NN of_IN Paxil_NNP CR_NNP by_IN GlaxoSmithKline_NNP in_IN 2002_CD ,_, the_DT 12_CD million_CD Deferred_NNP A_NNP Shares_NNP were_VBD automatically_RB converted_VBN into_IN 12_CD million_CD Ordinary_NNP Shares_NNP ._.
The_DT 12_CD million_CD Deferred_NNP B_NNP Shares_NNP automatically_RB convert_VBP to_TO 12_CD million_CD Ordinary_NNP Shares_NNP on_IN the_DT Companys_NNP receipt_NN of_IN a_DT royalty_NN statement_NN under_IN the_DT current_JJ licence_NN agreement_NN stating_VBG that_IN reported_VBD sales_NNS of_IN Paxil_NNP CR_NNP have_VBP exceeded_VBN $_$ 1,000_CD million_CD during_IN any_DT calendar_NN period_NN prior_RB to_TO 1_CD January_NNP 2006_CD or_CC exceeded_VBD $_$ 337_CD million_CD between_IN 1_CD January_NNP 2006_CD and_CC 3_CD May_NNP 2006_CD ._.
In_IN the_DT event_NN that_IN this_DT condition_NN is_VBZ not_RB satisfied_JJ prior_RB to_TO 3_CD May_NNP 2006_CD ,_, the_DT Deferred_NNP B_NNP Shares_NNP will_MD not_RB be_VB converted_VBN and_CC will_MD be_VB canceled_VBN ._.
The_DT vendor_NN will_MD not_RB be_VB entitled_VBN to_TO any_DT other_JJ nor_CC additional_JJ compensation_NN ._.
In_IN the_DT opinion_NN of_IN the_DT Directors_NNS this_DT condition_NN will_MD not_RB be_VB satisfied_VBN and_CC the_DT Deferred_NNP B_NNP Shares_NNP will_MD not_RB be_VB converted_VBN and_CC will_MD be_VB canceled_VBN ._.
The_DT Deferred_JJ A_DT and_CC B_NNP Shares_NNP were_VBD issued_VBN on_IN 20_CD July_NNP 2000_CD when_WRB the_DT price_NN of_IN an_DT Ordinary_NNP Share_NN was_VBD 94.25_CD pence_NN ._.
The_DT difference_NN between_IN the_DT nominal_JJ value_NN of_IN the_DT Deferred_NNP B_NNP Shares_NNP and_CC their_PRP$ fair_JJ value_NN ,_, taken_VBN to_TO be_VB 94.25_CD pence_NNS ,_, at_IN issue_NN has_VBZ been_VBN recorded_VBN as_IN non-equity_JJ share_NN premium_NN ._.
Warrants_NNS The_DT Company_NN has_VBZ the_DT following_JJ warrants_NNS outstanding_JJ :_: a_DT D_NNP and_CC E_NNP warrants_NNS The_DT D_NNP and_CC E_NNP Warrants_NNS were_VBD issued_VBN in_IN March_NNP 2002_CD as_IN part_NN of_IN the_DT consideration_NN for_IN the_DT agreement_NN with_IN Paul_NNP Capital_NNP to_TO fund_VB new_JJ product_NN development_NN ._.
The_DT D_NNP and_CC E_NNP Warrants_NNS entitle_VBP the_DT holders_NNS to_TO subscribe_VB for_IN a_DT total_NN of_IN 5_CD million_CD Ordinary_NNP Shares_NNP at_IN any_DT time_NN during_IN the_DT period_NN to_TO 31_CD December_NNP 2008_CD at_IN an_DT exercise_NN price_NN of_IN 73.75_CD pence_NN per_IN Ordinary_NNP Share_NNP ._.
A_DT value_NN of_IN 0.3_CD million_CD has_VBZ been_VBN attributed_VBN to_TO the_DT D_NNP and_CC E_NNP Warrants_NNS which_WDT has_VBZ been_VBN recorded_VBN within_IN Other_JJ Reserves_NNS ._.
b_NN F_NN warrants_NNS The_DT F_NN Warrants_NNS were_VBD issued_VBN in_IN December_NNP 2003_CD as_IN part_NN of_IN the_DT 2.7_CD million_CD $_$ 5_CD million_CD loan_NN with_IN GE_NNP Capital_NNP Corp._NNP ._.
The_DT F_NN Warrants_NNS entitle_VBP the_DT holders_NNS to_TO subscribe_VB for_IN a_DT total_NN of_IN 300,000_CD Ordinary_NNP Shares_NNP at_IN any_DT time_NN until_IN the_DT repayment_NN date_NN of_IN the_DT loan_NN at_IN an_DT exercise_NN price_NN of_IN 1.20_CD per_IN Ordinary_NNP Share_NNP ._.
A_DT value_NN of_IN 39,000_CD has_VBZ been_VBN attributed_VBN to_TO the_DT F_NN Warrants_NNS which_WDT has_VBZ been_VBN recorded_VBN within_IN Other_JJ Reserves_NNS ._.
c_NN Other_JJ warrants_NNS Warrants_NNS were_VBD issued_VBN in_IN December_NNP 1999_CD as_IN part_NN of_IN the_DT acquisition_NN of_IN DepoTech_NNP and_CC entitle_VB the_DT holders_NNS to_TO subscribe_VB for_IN 371,353_CD Ordinary_NNP Shares_NNP at_IN any_DT time_NN during_IN the_DT period_NN beginning_VBG 31_CD December_NNP 1999_CD and_CC ending_VBG on_IN 25_CD February_NNP 2005_CD at_IN an_DT exercise_NN price_NN of_IN $_$ 1.142_CD 59.5_CD pence_NN per_IN Ordinary_NNP Share_NNP ._.
All_DT of_IN these_DT warrants_NNS lapsed_VBD unexercised_JJ on_IN 25_CD February_NNP 2005_CD ._.
Share_NN Schemes_NNS The_DT Group_NNP encourages_VBZ employee_NN participation_NN in_IN its_PRP$ shares_NNS through_IN ownership_NN and_CC continues_VBZ to_TO operate_VB various_JJ incentive_NN schemes_NNS whereby_WRB Directors_NNS and_CC employees_NNS are_VBP to_TO able_JJ to_TO acquire_VB shares_NNS in_IN the_DT Company_NN ._.
Option_NN Schemes_NNP Options_NNPS granted_VBD to_TO UK_NNP and_CC European_JJ employees_NNS are_VBP only_RB exercisable_JJ between_IN the_DT third_JJ and_CC tenth_NN anniversary_NN of_IN the_DT date_NN of_IN grant_NN ,_, and_CC are_VBP subject_JJ to_TO the_DT Companys_NNP Code_NNP of_IN Conduct_NNP for_IN dealing_VBG in_IN Shares_NNP ,_, and_CC the_DT Model_NNP Code_NNP ._.
Options_NNS granted_VBN to_TO US_NNP employees_NNS prior_RB to_TO 2001_CD vest_NN at_IN 25_CD %_NN per_IN annum_NN from_IN the_DT date_NN of_IN grant_NN and_CC there_EX were_VBD no_DT performance_NN criteria_NNS ._.
UK_NNP and_CC European_JJ options_NNS granted_VBN prior_RB to_TO 2001_CD may_MD only_RB be_VB exercised_VBN if_IN the_DT growth_NN in_IN the_DT Companys_NNP share_NN price_NN over_IN a_DT consecutive_JJ three-year_JJ period_NN exceeds_VBZ the_DT growth_NN over_IN the_DT same_JJ period_NN in_IN the_DT FTSE_NNP All_NNP Share_NNP Index_NNP ._.
This_DT criteria_NNS was_VBD satisfied_VBN for_IN the_DT first_JJ time_NN in_IN March_NNP 2000_CD ._.
Employees_NNS with_IN options_NNS that_WDT are_VBP within_IN their_PRP$ exercise_NN period_NN are_VBP now_RB able_JJ to_TO exercise_VB those_DT options_NNS within_IN any_DT one-year_JJ period_NN from_IN the_DT date_NN the_DT performance_NN condition_NN is_VBZ satisfied_VBN ._.
Super_NNP Options_NNPS are_VBP exercisable_JJ after_IN five_CD years_NNS and_CC are_VBP subject_JJ to_TO higher_JJR performance_NN conditions_NNS in_IN accordance_NN with_IN those_DT recommended_VBN by_IN the_DT Association_NNP of_IN British_NNP Insurers_NNP ._.
Following_VBG changes_NNS to_TO the_DT option_NN plans_VBZ approved_VBN at_IN the_DT Annual_JJ General_NNP Meeting_VBG in_IN June_NNP 2001_CD ,_, options_NNS granted_VBN to_TO Directors_NNS and_CC senior_JJ employees_NNS since_IN that_DT date_NN are_VBP subject_JJ to_TO performance_NN conditions_NNS linked_VBN to_TO the_DT total_JJ shareholder_NN return_NN of_IN a_DT comparator_NN group_NN of_IN companies_NNS ,_, and_CC are_VBP not_RB subject_JJ to_TO retesting_VBG ._.
Options_NNS granted_VBN to_TO other_JJ US_NNP employees_NNS continue_VBP to_TO vest_NN at_IN 25_CD %_NN per_IN annum_NN with_IN no_DT performance_NN criteria_NNS ,_, and_CC other_JJ European_JJ employees_NNS who_WP are_VBP not_RB Directors_NNS or_CC senior_JJ employees_NNS can_MD exercise_VB their_PRP$ options_NNS after_IN three_CD years_NNS and_CC are_VBP not_RB subject_JJ to_TO performance_NN conditions_NNS ._.
The_DT Groups_NNS option_NN plans_NNS are_VBP detailed_VBN further_RBR in_IN the_DT Remuneration_NNP Report_NNP ._.
It_PRP is_VBZ the_DT intention_NN of_IN the_DT Group_NNP that_IN no_DT further_JJ options_NNS grants_NNS will_MD be_VB made_VBN under_IN any_DT of_IN the_DT option_NN plans_NNS ._.
64_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 23_CD Called_VBN up_RP share_NN capital_NN continued_VBD The_DT following_JJ table_NN summarises_VBZ the_DT activity_NN in_IN share_NN options_NNS for_IN the_DT years_NNS to_TO 31_CD December_NNP 2003_CD and_CC 31_CD December_NNP 2004_CD :_: Share_NN options_NNS Option_NN price_NN At_IN 1_CD January_NNP 2003_CD 40,456,933_CD 44.8_CD p_NN 93.0_CD p_NN Granted_VBN 16,153,237_CD 46.5_CD p_NN 62.0_CD p_NN Exercised_VBN 1,521,662_CD 44.8_CD p_NN 66.5_CD p_NN Cancelled_VBN or_CC expired_VBN 2,743,290_CD 44.8_CD p_NN 91.3_CD p_NN At_IN 31_CD December_NNP 2003_CD 52,345,218_CD 44.8_CD p_NN 93.0_CD p_NN Exercised_VBN 478,803_CD 44.8_CD p_NN 66.5_CD p_NN Cancelled_VBN or_CC expired_VBN 3,883,170_CD 46.5_CD p_NN 91.3_CD p_NN At_IN 31_CD December_NNP 2004_CD 47,983,245_CD 44.8_CD p_NN 93.0_CD p_NN The_DT market_NN value_NN of_IN Ordinary_NNP Shares_NNP as_IN at_IN 31_CD December_NNP 2004_CD was_VBD 65.5_CD pence_NN 31_CD December_NNP 2003_CD :_: 75.25_CD pence_NN ._.
The_DT market_NN value_NN of_IN Ordinary_NNP Shares_NNP during_IN 2004_CD ranged_VBD from_IN the_DT lowest_JJS closing_NN mid-price_NN of_IN 50.0_CD pence_NN to_TO the_DT highest_JJS closing_NN mid-price_NN of_IN 75.25_CD pence_NN per_IN share_NN ._.
Eligible_JJ employees_NNS are_VBP awarded_VBN rights_NNS to_TO acquire_VB a_DT maximum_JJ number_NN of_IN shares_NNS at_IN the_DT beginning_NN of_IN a_DT three_CD year_NN period_NN ,_, a_DT proportion_NN of_IN which_WDT they_PRP will_MD be_VB entitled_VBN to_TO receive_VB at_IN the_DT end_NN of_IN that_DT period_NN depending_VBG on_IN the_DT extent_NN to_TO which_WDT the_DT challenging_JJ performance_NN conditions_NNS set_VBN by_IN the_DT Remuneration_NNP Committee_NNP at_IN the_DT time_NN the_DT allocation_NN is_VBZ made_VBN are_VBP satisfied_VBN ._.
Further_JJ information_NN on_IN the_DT performance_NN conditions_NNS of_IN the_DT Long_NNP Term_NNP Incentive_NNP Plan_NNP are_VBP detailed_VBN in_IN the_DT Remuneration_NNP Report_NNP ._.
At_IN 31_CD December_NNP 2004_CD ,_, eligible_JJ employees_NNS hold_VBP rights_NNS over_IN Ordinary_NNP Shares_NNP which_WDT may_MD result_VB in_IN the_DT issue_NN of_IN shares_NNS of_IN 2,794,037_CD and_CC 798,232_CD on_IN 5_CD May_NNP 2007_CD and_CC 20_CD September_NNP 2007_CD ._.
International_NNP Share_NNP Purchase_NNP Plan_NNP All_NNP employees_NNS are_VBP eligible_JJ to_TO participate_VB in_IN the_DT International_NNP Share_NNP Purchase_NNP Plan_NNP whereby_WRB employees_NNS buy_VBP shares_NNS in_IN the_DT Company_NN ._.
These_DT shares_NNS are_VBP called_VBN Partnership_NNP Shares_NNP and_CC are_VBP held_VBN in_IN trust_NN on_IN behalf_NN of_IN the_DT employee_NN ._.
For_IN every_DT Partnership_NNP Share_NNP bought_VBD by_IN the_DT employee_NN the_DT Company_NN will_MD give_VB the_DT employee_NN one_CD share_NN free_JJ of_IN charge_NN Matching_NNP Shares_NNP ._.
The_DT employees_NNS have_VBP to_TO take_VB their_PRP$ shares_NNS out_IN of_IN the_DT plan_NN on_IN leaving_VBG the_DT Company_NN and_CC will_MD not_RB be_VB entitled_VBN to_TO the_DT Matching_NNP Shares_NNP if_IN they_PRP leave_VBP within_IN three_CD years_NNS of_IN buying_VBG the_DT Partnership_NNP Shares_NNP ._.
As_IN at_IN 31_CD December_NNP 2004_CD 289,560_CD Ordinary_NNP Shares_NNP had_VBD been_VBN issued_VBN by_IN the_DT Company_NN to_TO the_DT trust_NN at_IN par_JJ value_NN ._.
The_DT market_NN value_NN of_IN these_DT Ordinary_NNP Shares_NNP at_IN 31_CD December_NNP 2004_CD was_VBD approximately_RB 188,000_CD ._.
2004_CD SkyePharma_NNP Annual_JJ Report_NNP 65_CD 24_CD Shares_NNS and_CC warrants_NNS to_TO be_VB issued_VBN Group_NNP and_CC Company_NNP 000_CD At_IN 1_CD January_NNP 2004_CD and_CC 31_CD December_NNP 2004_CD a_DT Krypton_NNP The_NNP deferred_JJ consideration_NN on_IN the_DT acquisition_NN of_IN Krypton_NNP provides_VBZ that_IN a_DT maximum_NN of_IN 37.5_CD million_CD Ordinary_NNP Shares_NNP would_MD be_VB issued_VBN contingent_NN on_IN a_DT change_NN in_IN control_NN of_IN the_DT Company_NN at_IN a_DT share_NN price_NN of_IN not_RB less_JJR than_IN 80_CD pence_NNS compounded_VBN at_IN an_DT annual_JJ rate_NN of_IN 10_CD %_NN 1.89_CD as_RB at_IN 31_CD December_NNP 2004_CD ,_, or_CC satisfaction_NN of_IN various_JJ conditions_NNS and_CC hurdles_NNS which_WDT lapsed_VBD on_IN 31_CD December_NNP 2003_CD ._.
No_DT provision_NN for_IN deferred_JJ consideration_NN has_VBZ been_VBN recognized_VBN as_IN at_IN 31_CD December_NNP 2004_CD ._.
b_NN Paul_NNP Capital_NNP Royalty_NNP Acquisition_NNP Fund_NNP In_IN March_NNP 2002_CD the_DT Group_NNP announced_VBD a_DT second_JJ transaction_NN with_IN Paul_NNP Capital_NNP Royalty_NNP Acquisition_NNP Fund_NNP under_IN which_WDT SkyePharma_NNP would_MD issue_VB Ordinary_NNP Shares_NNP up_IN to_TO a_DT value_NN of_IN $_$ 7.5_CD million_CD if_IN royalties_NNS and_CC milestones_NNS received_VBN by_IN SkyePharma_NNP in_IN respect_NN of_IN those_DT products_NNS included_VBD in_IN the_DT transaction_NN were_VBD not_RB in_IN excess_NN of_IN minimum_JJ annual_JJ payments_NNS required_VBN to_TO be_VB made_VBN to_TO Paul_NNP Capital_NNP ._.
During_IN 2004_CD the_DT royalties_NNS received_VBN by_IN SkyePharma_NNP were_VBD substantially_RB in_IN excess_NN of_IN the_DT minimum_JJ payments_NNS required_VBN to_TO be_VB made_VBN to_TO Paul_NNP Capital_NNP ,_, consequently_RB the_DT company_NN has_VBZ not_RB recognized_VBN a_DT provision_NN ._.
25_CD Reserves_NNS Equity_NNP Non-equity_JJ share_NN share_NN Profit_NN and_CC premium_NN premium_NN Other_JJ loss_NN account_NN account_NN account_NN reserves_NNS restated_VBN Group_NNP 000 000 000 000_CD At_IN 1_CD January_NNP 2004_CD 309,113_CD 10,110_CD 9,350_CD 306,770_CD Exchange_NNP adjustments_NNS 531_CD On_IN issue_NN of_IN shares_NNS to_TO RDF_NNP 1,544_CD On_IN exercise_NN of_IN share_NN options_NNS 213_CD ESOP_NNP credit_NN 1,278_CD Loss_NN for_IN the_DT year_NN 24,296_CD Unrealised_NNP gain_NN on_IN contract_NN development_NN 130_CD Unrealised_JJ interest_NN receivable_NN 42_CD At_IN 31_CD December_NNP 2004_CD 310,870_CD 10,110_CD 9,350_CD 330,147_CD Other_JJ reserves_NNS are_VBP non_JJ distributable_JJ and_CC relate_VB to_TO a_DT merger_NN reserve_NN on_IN acquisition_NN and_CC a_DT warrant_NN reserve_NN on_IN the_DT issue_NN of_IN the_DT D_NNP ,_, E_NNP and_CC F_NN Warrants_NNS ._.
As_IN at_IN 31_CD December_NNP 2004_CD the_DT cumulative_JJ amount_NN of_IN goodwill_NN eliminated_VBN against_IN reserves_NNS was_VBD 147,632,000_CD 2003_CD :_: 147,632,000_CD ._.
Equity_NNP Non-equity_JJ share_NN share_NN Profit_NN and_CC premium_NN premium_NN Other_JJ loss_NN account_NN account_NN account_NN reserves_NNS restated_VBN Company_NN 000 000 000 000_CD At_IN 1_CD January_NNP 2004_CD 309,113_CD 10,110_CD 9,350_CD 18,564_CD On_IN issue_NN of_IN shares_NNS 1,544_CD On_IN exercise_NN of_IN share_NN options_NNS 213_CD ESOP_NNP credit_NN 1,278_CD Loss_NN for_IN the_DT year_NN 26,905_CD At_IN 31_CD December_NNP 2004_CD 310,870_CD 10,110_CD 9,350_CD 44,191_CD As_IN permitted_VBN by_IN Section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, the_DT Profit_NN and_CC Loss_NN Account_NNP of_IN the_DT Company_NN is_VBZ not_RB presented_VBN ._.
The_DT loss_NN of_IN the_DT Company_NN for_IN the_DT financial_JJ year_NN was_VBD 26,905,000_CD 2003_CD :_: 821,000_CD ._.
66_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 26_CD Financial_NNP instruments_NNS The_DT Group_NNP holds_VBZ financial_JJ instruments_NNS to_TO finance_VB its_PRP$ operations_NNS and_CC to_TO manage_VB the_DT currency_NN risk_NN that_WDT arises_VBZ from_IN these_DT operations_NNS ._.
The_DT Group_NNP finances_VBZ its_PRP$ operations_NNS through_IN a_DT combination_NN of_IN equity_NN ,_, convertible_JJ bonds_NNS ,_, bank_NN loans_NNS and_CC other_JJ borrowings_NNS ._.
The_DT main_JJ risks_NNS arising_VBG from_IN the_DT Groups_NNS financial_JJ instruments_NNS are_VBP liquidity_NN risk_NN ,_, foreign_JJ currency_NN risk_NN ,_, interest_NN rate_NN risk_NN and_CC credit_NN risk_NN ._.
Liquidity_NN risk_NN The_DT Groups_NNS policy_NN is_VBZ to_TO maintain_VB continuity_NN of_IN funding_VBG through_IN a_DT mixture_NN of_IN long-term_JJ debt_NN and_CC bank_NN loans_NNS ,_, raised_VBD to_TO cover_VB specific_JJ projects_NNS ,_, and_CC through_IN the_DT issue_NN of_IN shares_NNS to_TO collaborative_JJ partners_NNS ,_, where_WRB necessary_JJ ,_, to_TO finance_VB development_NN contracts_NNS ._.
Short-term_JJ flexibility_NN is_VBZ provided_VBN through_IN the_DT use_NN of_IN overdrafts_NNS ._.
The_DT maturity_NN profile_NN of_IN the_DT Groups_NNS debt_NN is_VBZ set_VBN out_RP below_IN at_IN note_NN c._NN Foreign_JJ currency_NN risk_NN All_DT of_IN the_DT Groups_NNS operations_NNS are_VBP based_VBN overseas_RB in_IN Continental_NNP Europe_NNP and_CC North_NNP America_NNP giving_VBG rise_NN to_TO exposures_NNS to_TO changes_NNS in_IN foreign_JJ exchange_NN rates_NNS notably_RB the_DT Swiss_JJ Franc_NN ,_, Euro_NNP and_CC US_NNP Dollar_NNP ._.
To_TO minimize_VB the_DT impact_NN of_IN any_DT fluctuations_NNS ,_, the_DT Groups_NNS policy_NN has_VBZ historically_RB been_VBN to_TO maintain_VB natural_JJ hedges_NNS by_IN relating_VBG the_DT structure_NN of_IN borrowings_NNS to_TO the_DT trading_NN cash_NN flows_VBZ that_IN generate_VB them_PRP ._.
Where_WRB subsidiaries_NNS are_VBP funded_VBN centrally_RB ,_, this_DT is_VBZ achieved_VBN by_IN the_DT use_NN of_IN long-term_JJ loans_NNS ,_, the_DT exchange_NN differences_NNS on_IN which_WDT are_VBP taken_VBN to_TO reserves_NNS ._.
Where_WRB it_PRP has_VBZ not_RB been_VBN possible_JJ to_TO use_VB natural_JJ hedges_NNS ,_, currency_NN options_NNS ,_, accrual_NN forward_RB options_NNS and_CC forward_JJ currency_NN contracts_NNS are_VBP used_VBN ._.
The_DT Group_NNP has_VBZ used_VBN these_DT financial_JJ instruments_NNS during_IN the_DT year_NN to_TO minimize_VB the_DT currency_NN exposure_NN on_IN operational_JJ transactions_NNS ._.
Interest_NN rate_NN risk_NN The_DT Group_NNP borrows_VBZ at_IN fixed_VBN and_CC floating_VBG rates_NNS of_IN interest_NN as_IN deemed_VBN appropriate_JJ for_IN its_PRP$ circumstances_NNS ._.
Where_WRB necessary_JJ the_DT Group_NNP uses_VBZ interest_NN rate_NN swaps_NNS to_TO achieve_VB the_DT desired_VBN interest_NN rate_NN profile_NN including_VBG a_DT cancellable_JJ fixed_VBN to_TO floating_VBG rate_NN interest_NN rate_NN swap_NN on_IN 30_CD million_CD of_IN the_DT 6_CD %_NN convertible_JJ bond_NN liability_NN ._.
The_DT interest_NN rate_NN profile_NN of_IN the_DT Groups_NNS financial_JJ assets_NNS and_CC liabilities_NNS is_VBZ set_VBN out_RP in_IN notes_NNS a_DT and_CC b_NN respectively_RB ._.
Credit_NNP risk_NN The_NNP Group_NNP is_VBZ exposed_VBN to_TO credit_NN related_VBN losses_NNS in_IN the_DT event_NN of_IN non-performance_JJ by_IN third_JJ parties_NNS to_TO financial_JJ instruments_NNS ._.
The_DT Group_NNP does_VBZ not_RB expect_VB any_DT third_JJ parties_NNS to_TO fail_VB to_TO meet_VB their_PRP$ obligations_NNS given_VBN the_DT policy_NN of_IN selecting_VBG only_RB parties_NNS with_IN high_JJ credit_NN ratings_NNS and_CC minimizing_VBG its_PRP$ exposure_NN to_TO any_DT one_CD institution_NN ._.
In_IN the_DT numerical_JJ disclosures_NNS that_WDT follow_VBP ,_, short-term_JJ debtors_NNS and_CC creditors_NNS that_WDT arise_VBP directly_RB as_IN a_DT result_NN of_IN the_DT Groups_NNS operations_NNS are_VBP excluded_VBN from_IN all_DT disclosures_NNS with_IN the_DT exception_NN of_IN note_NN f_SYM on_IN currency_NN exposures_NNS ._.
a_DT Interest_NN rate_NN and_CC currency_NN profile_NN of_IN financial_JJ assets_NNS 31_CD December_NNP 2004_CD Weighted_JJ average_JJ Weighted_NNP Noninterest_NNP rate_NN average_JJ Floating_VBG interest_NN Fixed_VBN rate_NN on_IN fixed_JJ rate_NN time_NN for_IN rate_NN bearing_NN Total_JJ financial_JJ financial_JJ which_WDT rate_NN financial_JJ financial_JJ financial_JJ assets_NNS assets_NNS is_VBZ fixed_VBN assets_NNS assets_NNS assets_NNS Currency_NNP 000_CD %_NN months_NNS 000 000 000_CD Sterling_NNP 1,093_CD 5.00_CD 30.0_CD 7,822_CD 4,120_CD 13,035_CD $_$ US_PRP 521_CD 12.00_CD 47.5_CD 4,744_CD 14,903_CD 20,168_CD Swiss_JJ francs_NNS 365 590 955_CD $_$ Canadian_JJ 655_CD 1,077_CD 1,732_CD Euro_NNP 966_CD 387_CD 1,353_CD Swedish_NNP Krona_NNP 61_CD 61_CD 1,614_CD 7.26_CD 35.6_CD 14,613_CD 21,077_CD 37,304_CD Total_JJ financial_JJ assets_NNS comprise_VBP fixed_VBN asset_NN investments_NNS of_IN 20.1_CD million_CD 2003_CD :_: 22.0_CD million_CD ,_, current_JJ asset_NN investments_NNS of_IN 1.1_CD million_CD 2003_CD :_: 1.0_CD million_CD ,_, debtors_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN of_IN 0.8_CD million_CD 2003_CD :_: 0.8_CD million_CD and_CC cash_NN and_CC short-term_JJ bank_NN deposits_NNS of_IN 15.3_CD million_CD 2003_CD :_: 23.2_CD million_CD ._.
Floating_VBG rate_NN financial_JJ assets_NNS bear_VBP interest_NN at_IN rates_NNS based_VBN upon_IN the_DT floating_VBG base_NN rate_NN in_IN the_DT country_NN in_IN which_WDT the_DT funds_NNS are_VBP held_VBN ._.
2004_CD SkyePharma_NNP Annual_JJ Report_NNP 67_CD 26_CD Financial_NNP instruments_NNS continued_VBD 31_CD December_NNP 2003_CD Weighted_JJ average_JJ Weighted_NNP Noninterest_NNP rate_NN average_JJ Floating_VBG interest_NN Fixed_VBN rate_NN on_IN fixed_JJ rate_NN time_NN for_IN rate_NN bearing_NN Total_JJ financial_JJ financial_JJ which_WDT rate_NN financial_JJ financial_JJ financial_JJ assets_NNS assets_NNS is_VBZ fixed_VBN assets_NNS assets_NNS assets_NNS Currency_NNP 000_CD %_NN months_NNS 000 000 000_CD Sterling_NNP 7,981_CD 4.94_CD 15.2_CD 6,016_CD 2,129_CD 16,126_CD $_$ US_PRP 568_CD 12.00_CD 59.5_CD 7,335_CD 18,728_CD 26,631_CD Swiss_JJ francs_NNS 192_CD 2_CD 194_CD $_$ Canadian_JJ 821_CD 1,431_CD 2,252_CD Euro_NNP 1,170_CD 64_CD 1,234_CD Swedish_NNP Krona_NNP 610_CD 610_CD 8,549_CD 5.41_CD 18.1_CD 16,144_CD 22,354_CD 47,047_CD b_NN Interest_NN rate_NN and_CC currency_NN profile_NN of_IN financial_JJ liabilities_NNS The_DT interest_NN rate_NN risk_NN profile_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS after_IN taking_VBG into_IN account_NN the_DT interest_NN rate_NN and_CC currency_NN swaps_NNS used_VBN to_TO manage_VB the_DT interest_NN and_CC currency_NN profile_NN was_VBD :_: 31_CD December_NNP 2004_CD Weighted_JJ average_JJ Weighted_NNP Noninterest_NNP rate_NN average_JJ Floating_VBG interest_NN Weighted_NNP Fixed_NNP rate_NN on_IN fixed_JJ rate_NN time_NN for_IN rate_NN bearing_NN average_JJ Total_JJ financial_JJ financial_JJ which_WDT rate_NN financial_JJ financial_JJ time_NN to_TO financial_JJ liabilities_NNS liabilities_NNS is_VBZ fixed_VBN liabilities_NNS liabilities_NNS maturity_NN liabilities_NNS Currency_NNP 000_CD %_NN months_NNS 000_CD 000_CD months_NNS 000_CD Sterling_NNP 49,400_CD 6.00_CD 5.5_CD 30,000_CD 11,310_CD 16.0_CD 90,710_CD $_$ US_PRP 1,933_CD 8.07_CD 5.6_CD 2,954_CD 129.0_CD 4,887_CD Swiss_JJ francs_NNS 7,449_CD 6.29_CD 6.6_CD 1,603_CD 9,052_CD $_$ Canadian_JJ 349_CD 96.0_CD 349_CD Swedish_NNP Krona_NNP 50_CD 50_CD 58,782_CD 6.10_CD 5.6_CD 31,653_CD 14,613_CD 40.8_CD 105,048_CD Financial_NNP liabilities_NNS comprise_VBP total_JJ borrowings_NNS of_IN 10.9_CD million_CD 2003_CD :_: 13.6_CD million_CD ,_, convertible_JJ bonds_NNS of_IN 79.4_CD million_CD 2003_CD :_: 59.4_CD million_CD ,_, non-equity_JJ Deferred_NNP B_NNP Shares_NNP of_IN 11.3_CD million_CD 2003_CD :_: 11.3_CD million_CD and_CC other_JJ creditors_NNS of_IN 3.4_CD million_CD 2003_CD :_: 3.8_CD million_CD ._.
The_DT effect_NN of_IN the_DT Groups_NNS interest_NN rate_NN swap_NN is_VBZ to_TO classify_VB 30.0_CD million_CD of_IN the_DT convertible_JJ bonds_NNS in_IN the_DT above_JJ table_NN as_IN a_DT floating_VBG rate_NN financial_JJ liability_NN ._.
Total_JJ financial_JJ liabilities_NNS does_VBZ not_RB agree_VB to_TO the_DT total_NN of_IN the_DT balance_NN sheet_NN captions_NNS due_JJ to_TO the_DT presence_NN of_IN 3,148,000_CD 2003_CD :_: 609,000_CD of_IN unamortised_JJ issue_NN costs_NNS within_IN the_DT value_NN shown_VBN on_IN the_DT balance_NN sheet_NN for_IN convertible_JJ bonds_NNS ._.
All_DT floating_VBG rate_NN financial_JJ liabilities_NNS ,_, in_IN both_DT 2004_CD and_CC 2003_CD ,_, are_VBP interest_NN bearing_NN financial_JJ liabilities_NNS that_WDT bear_VBP interest_NN at_IN interest_NN rates_NNS based_VBN on_IN LIBOR_NNP ,_, prime_JJ and_CC other_JJ bank_NN based_VBN lending_NN rates_NNS in_IN the_DT country_NN in_IN which_WDT the_DT liability_NN arises_VBZ ,_, which_WDT are_VBP fixed_VBN for_IN periods_NNS of_IN up_RB to_TO 12_CD months_NNS ._.
68_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 26_CD Financial_NNP instruments_NNS continued_VBD 31_CD December_NNP 2003_CD Weighted_JJ average_JJ Weighted_NNP Noninterest_NNP rate_NN average_JJ Floating_VBG interest_NN Weighted_NNP Fixed_NNP rate_NN on_IN fixed_JJ rate_NN time_NN for_IN rate_NN bearing_NN average_JJ Total_JJ financial_JJ financial_JJ which_WDT rate_NN financial_JJ financial_JJ time_NN to_TO financial_JJ liabilities_NNS liabilities_NNS is_VBZ fixed_VBN liabilities_NNS liabilities_NNS maturity_NN liabilities_NNS Currency_NNP 000_CD %_NN months_NNS 000_CD 000_CD months_NNS 000_CD Sterling_NNP 29,400_CD 6.00_CD 17.5_CD 30,000_CD 11,310_CD 28.0_CD 70,710_CD $_$ US_PRP 2,701_CD 7.99_CD 35.7_CD 559_CD 3,070_CD 136.0_CD 6,330_CD Swiss_JJ francs_NNS 4,496_CD 3.66_CD 23.0_CD 5,940_CD 10,436_CD $_$ Canadian_JJ 389_CD 120.0_CD 389_CD Swedish_NNP Krona_NNP 235_CD 6.38_CD 26.2_CD 235_CD 36,832_CD 5.86_CD 19.6_CD 36,499_CD 14,769_CD 52.9_CD 88,100_CD c_NN Maturity_NN of_IN financial_JJ liabilities_NNS 31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000_CD Within_IN one_CD year_NN 13,682_CD 4,530_CD Between_IN one_CD and_CC two_CD years_NNS 11,625_CD 60,662_CD Between_IN two_CD and_CC five_CD years_NNS 70,439_CD 13,261_CD Beyond_NNP five_CD years_NNS 9,302_CD 9,647_CD 105,048_CD 88,100_CD d_SYM Borrowing_VBG facilities_NNS As_IN at_IN 31_CD December_NNP 2004_CD the_DT Group_NNP had_VBD the_DT following_VBG Swiss_JJ franc_NN undrawn_JJ committed_JJ borrowing_NN facilities_NNS available_JJ ._.
31_CD December_NNP 2004_CD 31_CD December_NNP 2003 000 000_CD Expiring_VBG within_IN one_CD year_NN 1,374_CD 158_CD e_SYM Fair_NNP values_VBZ The_DT comparison_NN of_IN fair_JJ and_CC book_NN values_NNS of_IN all_PDT the_DT Groups_NNS financial_JJ instruments_NNS as_IN at_IN 31_CD December_NNP 2004_CD is_VBZ set_VBN out_RP below_IN ._.
Market_NN value_NN ,_, or_CC Directors_NNS valuation_NN if_IN a_DT market_NN value_NN is_VBZ unavailable_JJ ,_, have_VBP been_VBN used_VBN to_TO determine_VB the_DT fair_JJ value_NN of_IN fixed_VBN and_CC current_JJ asset_NN investments_NNS ._.
Market_NN values_NNS have_VBP been_VBN used_VBN to_TO determine_VB the_DT fair_JJ values_NNS of_IN the_DT convertible_JJ bonds_NNS ._.
Market_NN values_NNS have_VBP been_VBN used_VBN to_TO determine_VB the_DT fair_JJ values_NNS of_IN all_DT swaps_NNS and_CC foreign_JJ currency_NN contracts_NNS ._.
The_DT fair_JJ value_NN of_IN the_DT non-equity_JJ Deferred_NNP B_NNP Shares_NNP has_VBZ been_VBN determined_VBN at_IN Nil_NNP since_IN in_IN the_DT opinion_NN of_IN the_DT Directors_NNS the_DT Deferred_NNP B_NNP Shares_NNP will_MD not_RB be_VB converted_VBN and_CC will_MD be_VB canceled_VBN ._.
See_VB note_NN 23_CD :_: Called_VBN up_RP share_NN capital_NN ,_, for_IN details_NNS of_IN the_DT contingencies_NNS that_WDT shall_MD determine_VB the_DT issuance_NN of_IN the_DT Ordinary_NNP Shares_NNP ._.
The_DT fair_JJ values_NNS of_IN all_DT other_JJ items_NNS have_VBP been_VBN calculated_VBN by_IN discounting_VBG future_JJ cash_NN flows_VBZ at_IN interest_NN rates_NNS prevailing_VBG at_IN 31_CD December_NNP 2004_CD ._.
2004_CD SkyePharma_NNP Annual_JJ Report_NNP 69_CD 26_CD Financial_NNP instruments_NNS continued_VBD 31_CD December_NNP 2004_CD Book_NNP values_NNS Fair_NNP values_VBZ 000_CD 000_CD Financial_NNP instruments_NNS held_VBD or_CC issued_VBD to_TO finance_VB the_DT Groups_NNS operations_NNS Fixed_VBN asset_NN investments_NNS 20,104_CD 14,837_CD Debtors_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN 770_CD 770_CD Current_JJ asset_NN investments_NNS 1,093_CD 1,093_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 14,687_CD 14,687_CD Short-term_JJ bank_NN deposits_NNS 650_CD 650_CD Short-term_JJ borrowings_NNS and_CC current_JJ portion_NN of_IN long-term_JJ borrowings_NNS 3,876_CD 3,876_CD Short-term_JJ convertible_JJ debt_NN 9,806_CD 9,975_CD Long-term_JJ convertible_JJ debt_NN 69,594_CD 75,892_CD Other_JJ long-term_JJ debt_NN 10,462_CD 10,462_CD Non-equity_NN Deferred_VBN B_NNP Shares_NNP 11,310_CD 67,744_CD 68,168_CD Derivative_JJ financial_JJ instruments_NNS held_VBN to_TO manage_VB the_DT Groups_NNS currency_NN profile_NN Interest_NN rate_NN swaps_NNS 164_CD Forward_RB currency_NN contracts_NNS 2_CD 162_CD 31_CD December_NNP 2003_CD Book_NNP values_NNS Fair_NNP values_VBZ 000_CD 000_CD Financial_NNP instruments_NNS held_VBD or_CC issued_VBD to_TO finance_VB the_DT Groups_NNS operations_NNS Fixed_VBN asset_NN investments_NNS 22,024_CD 28,745_CD Debtors_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN 802_CD 802_CD Current_JJ asset_NN investments_NNS 981_CD 981_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 3,052_CD 3,052_CD Short-term_JJ bank_NN deposits_NNS 20,188_CD 20,188_CD Short-term_JJ borrowings_NNS and_CC current_JJ portion_NN of_IN long-term_JJ borrowings_NNS 4,530_CD 4,530_CD Long-term_JJ convertible_JJ debt_NN 59,400_CD 56,218_CD Other_JJ long-term_JJ debt_NN 12,860_CD 12,860_CD Non-equity_NN Deferred_VBN B_NNP Shares_NNP 11,310_CD 9,030_CD 41,053_CD 28,870_CD Derivative_JJ financial_JJ instruments_NNS held_VBN to_TO manage_VB the_DT Groups_NNS currency_NN profile_NN Interest_NN rate_NN swaps_NNS 322_CD Canadian_JJ $_$ currency_NN options_NNS Euro_NNP currency_NN options_NNS 21_CD Swiss_JJ franc_NN currency_NN options_NNS 12_CD Swedish_JJ Krona_NNP currency_NN options_NNS 59_CD Forward_RB currency_NN contracts_NNS 18_CD 354_CD 70_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 26_CD Financial_NNP instruments_NNS continued_VBD f_SYM Currency_NNP exposures_NNS The_DT following_JJ analysis_NN shows_VBZ the_DT net_JJ monetary_JJ assets_NNS and_CC liabilities_NNS of_IN Group_NNP companies_NNS that_WDT are_VBP not_RB denominated_VBN in_IN their_PRP$ functional_JJ currency_NN and_CC therefore_RB give_VB rise_VB to_TO exchange_VB gains_NNS and_CC losses_NNS in_IN the_DT profit_NN and_CC loss_NN account_NN in_IN both_DT 2004_CD and_CC 2003_CD ._.
31_CD December_NNP 2004_CD Net_JJ foreign_JJ currency_NN monetary_JJ assets_NNS liabilities_NNS Swiss_JJ $_$ Swedish_JJ Sterling_NN $_$ US_PRP Euro_NNP francs_NNS Canadian_JJ Krona_NNP Total_NNP Functional_NNP currency_NN of_IN Operating_VBG Company_NN 000 000 000 000_CD 000 000 000_CD Sterling_NNP 778_CD 161_CD 1_CD 655_CD 1,595_CD $_$ US_PRP 19,020_CD 206_CD 1,346_CD 17,468_CD Euro_NNP 205_CD 6_CD 5,713_CD 244_CD 5,758_CD Swiss_JJ francs_NNS 1,618_CD 2,297_CD 27_CD 2,774_CD 425_CD 3,851_CD $_$ Canadian_JJ 577_CD 1,521_CD 244_CD 2,342_CD Swedish_NNP Krona_NNP 4,741_CD 356_CD 5,097_CD 22,925_CD 3,390_CD 150_CD 5,714_CD 529_CD 425_CD 21,405_CD 31_CD December_NNP 2003_CD Net_JJ foreign_JJ currency_NN monetary_JJ assets_NNS liabilities_NNS Swiss_JJ $_$ Swedish_JJ Sterling_NN $_$ US_PRP Euro_NNP francs_NNS Canadian_JJ Krona_NNP Total_NNP Functional_NNP currency_NN of_IN Operating_VBG Company_NN 000 000 000 000_CD 000 000 000_CD Sterling_NNP 3,796_CD 847_CD 6_CD 4,649_CD $_$ US_PRP 3,579_CD 65_CD 3,644_CD Euro_NNP 245_CD 17_CD 2,622_CD 2,850_CD Swiss_JJ francs_NNS 10,280_CD 2,419_CD 220_CD 5_CD 12,474_CD $_$ Canadian_JJ 1,038_CD 1,391_CD 71_CD 424_CD Swedish_NNP Krona_NNP 2,568_CD 54_CD 2,622_CD 5,416_CD 4,753_CD 491_CD 2,622_CD 6_CD 5_CD 13,283_CD g_NN Hedging_NNP As_IN explained_VBN above_IN ,_, the_DT Groups_NNS policy_NN is_VBZ to_TO hedge_VB interest_NN rate_NN exposures_NNS through_IN the_DT use_NN of_IN interest_NN rate_NN swaps_NNS and_CC currency_NN exposures_NNS through_IN the_DT use_NN of_IN currency_NN options_NNS ,_, accrual_NN forward_RB options_NNS and_CC forward_JJ currency_NN contracts_NNS ._.
The_DT table_NN below_IN shows_NNS the_DT extent_NN to_TO which_WDT the_DT Group_NNP has_VBZ off-balance_JJ sheet_NN unrecognised_JJ gains_NNS and_CC losses_NNS in_IN respect_NN of_IN hedges_NNS at_IN the_DT beginning_NN and_CC end_NN of_IN the_DT year_NN :_: 31_CD December_NNP 2004_CD Gains_NNS Losses_NNS Net_JJ total_NN 000 000 000_CD Unrecognised_JJ gains_NNS and_CC losses_NNS at_IN the_DT beginning_NN of_IN the_DT year_NN 393_CD 39_CD 354_CD Gains_NNS and_CC losses_NNS arising_VBG in_IN previous_JJ years_NNS and_CC recognized_VBN in_IN the_DT year_NN 393_CD 39_CD 354_CD Gains_NNS and_CC losses_NNS arising_VBG before_IN the_DT beginning_NN of_IN the_DT year_NN and_CC still_RB unrecognised_JJ at_IN the_DT end_NN of_IN the_DT year_NN Unrecognised_JJ gains_NNS and_CC losses_NNS arising_VBG in_IN the_DT year_NN 2_CD 164_CD 162_CD Total_JJ unrecognised_JJ gains_NNS and_CC losses_NNS at_IN the_DT end_NN of_IN the_DT year_NN 2_CD 164 162 2004_CD SkyePharma_NNP Annual_JJ Report_NNP 71_CD 26_CD Financial_NNP instruments_NNS continued_VBD g_JJ Hedging_NNP continued_VBD At_IN 31_CD December_NNP 2004_CD ,_, the_DT Group_NNP had_VBD an_DT unrecognised_JJ gain_NN of_IN approximately_RB 2,000_CD arising_VBG from_IN a_DT Swedish_JJ Krona_NNP swap_NN of_IN SKR_NNP 7.2_CD million_CD ._.
The_DT Group_NNP had_VBD an_DT unrecognised_JJ loss_NN at_IN 31_CD December_NNP 2004_CD of_IN approximately_RB 164,000_CD relating_VBG to_TO a_DT cancellable_JJ interest_NN rate_NN swap_NN agreement_NN which_WDT expires_VBZ in_IN June_NNP 2005_CD ._.
31_CD December_NNP 2003_CD Gains_NNS Losses_NNS Net_JJ total_NN 000 000 000_CD Unrecognised_JJ gains_NNS and_CC losses_NNS at_IN the_DT beginning_NN of_IN the_DT year_NN 598_CD 98_CD 500_CD Gains_NNS and_CC losses_NNS arising_VBG in_IN previous_JJ years_NNS and_CC recognized_VBN in_IN the_DT year_NN 146_CD 98_CD 48_CD Gains_NNS and_CC losses_NNS arising_VBG before_IN the_DT beginning_NN of_IN the_DT year_NN and_CC still_RB unrecognised_JJ at_IN the_DT end_NN of_IN the_DT year_NN 452_CD 452_CD Unrecognised_JJ gains_NNS and_CC losses_NNS arising_VBG in_IN the_DT year_NN 59_CD 39_CD 98_CD Total_JJ unrecognised_JJ gains_NNS and_CC losses_NNS at_IN the_DT end_NN of_IN the_DT year_NN 393_CD 39_CD 354_CD 27_CD Pension_NN arrangements_NNS The_DT Group_NNP operates_VBZ various_JJ defined_VBN contribution_NN plans_NNS for_IN its_PRP$ employees_NNS in_IN the_DT UK_NNP ,_, Switzerland_NNP and_CC US_NNP ._.
The_DT Groups_NNS contributions_NNS to_TO these_DT plans_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN the_DT period_NN to_TO which_WDT they_PRP relate_VBP ,_, and_CC the_DT assets_NNS are_VBP held_VBN in_IN separate_JJ trustee_NN administered_VBN funds_NNS ._.
The_DT Group_NNP operates_VBZ an_DT unfunded_JJ defined_VBN benefit_NN scheme_NN in_IN respect_NN of_IN its_PRP$ employees_NNS in_IN France_NNP based_VBN on_IN the_DT national_JJ collective_JJ agreement_NN of_IN the_DT pharmaceutical_JJ industry_NN ,_, and_CC a_DT provision_NN of_IN 416,000_CD is_VBZ included_VBN in_IN note_NN 19_CD :_: Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS in_IN respect_NN of_IN these_DT obligations_NNS ._.
The_DT scheme_NN was_VBD amended_VBN in_IN 2003_CD due_JJ to_TO the_DT introduction_NN of_IN the_DT Fillon_NNP law_NN in_IN France_NNP ._.
The_DT consequent_JJ increase_NN in_IN past_JJ service_NN costs_NNS is_VBZ being_VBG amortised_VBN over_IN the_DT remaining_VBG average_NN expected_VBN active_JJ life_NN of_IN the_DT employees_NNS ._.
Under_IN the_DT transitional_JJ provisions_NNS of_IN FRS17_NNP :_: Retirement_NNP Benefits_NNPS certain_JJ disclosures_NNS for_IN the_DT defined_VBN benefit_NN scheme_NN in_IN France_NNP are_VBP required_VBN as_IN follows_VBZ :_: As_IN at_IN 31_CD December_NNP 2004_CD a_DT valuation_NN was_VBD performed_VBN by_IN professionally_RB qualified_VBN actuaries_NNS ,_, Socit_NNP fide_NNP Prospective_JJ Actuariat_NNP et_NNP Conseil_NNP ,_, on_IN the_DT present_JJ value_NN of_IN the_DT accrued_VBN liabilities_NNS calculated_VBN under_IN the_DT projected_VBN unit_NN method_NN ._.
The_DT principal_JJ assumptions_NNS made_VBN by_IN the_DT actuaries_NNS were_VBD :_: 2004 2003 2002_CD %_NN per_IN %_NN per_IN %_NN per_IN annum_NN annum_NN annum_NN Inflation_NN rate_NN 1.75_CD 1.75_CD 1.75_CD Rate_NN of_IN increase_NN in_IN salaries_NNS 2.75_CD 2.75_CD 2.75_CD Discount_NNP rate_NN 4.75_CD 5.25_CD 5.25_CD Analysis_NN of_IN amounts_NNS charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN respect_NN of_IN the_DT defined_VBN benefit_NN scheme_NN under_IN FRS_NNP 17 2004 2003 000_CD 000_CD Current_JJ service_NN cost_NN 34_CD 18_CD Past_JJ service_NN cost_NN 14_CD Interest_NN on_IN pension_NN scheme_NN liabilities_NNS 29_CD 22_CD Total_JJ charge_NN to_TO the_DT profit_NN and_CC loss_NN account_NN 77_CD 40_CD 72_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 27_CD Pension_NNP arrangements_NNS continued_VBD Movement_NNP in_IN deficit_NN during_IN the_DT year_NN 2004 2003 000 000_CD Opening_NNP deficit_NN 603_CD 382_CD Exchange_NNP adjustment_NN 8_CD 31_CD Current_JJ service_NN cost_NN 34_CD 18_CD Contributions_NNS 26_CD Interest_NN on_IN pension_NN scheme_NN liabilities_NNS 29_CD 22_CD Unrecognised_JJ past_JJ service_NN cost_NN 183_CD Actuarial_JJ loss_NN gain_NN recognized_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 45_CD 33_CD Closing_NN deficit_NN 693_CD 603_CD Amounts_NNS recorded_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS under_IN FRS17_NNP 2004_CD 2003_CD Experience_NN losses_NNS gains_NNS arising_VBG on_IN scheme_NN liabilities_NNS 000_CD 5_CD 24_CD Percentage_NN of_IN scheme_NN liabilities_NNS %_NN 1_CD 6_CD Changes_NNS in_IN assumption_NN relating_VBG to_TO the_DT present_JJ value_NN of_IN scheme_NN liabilities_NNS 000_CD 40_CD 9_CD Percentage_NN of_IN scheme_NN liabilities_NNS %_NN 6_CD 2_CD Total_JJ actuarial_JJ loss_NN gain_NN 000_CD 45_CD 33_CD Percentage_NN of_IN scheme_NN liabilities_NNS %_NN 7_CD 8_CD Provision_NNP under_IN FRS17_NNP 2003_CD 2004_CD restated_VBN 000_CD 000_CD Pension_NN liability_NN under_IN SSAP_NNP 24_CD :_: Accounting_NNP for_IN pension_NN costs_NNS 416_CD 285_CD Unrecognised_JJ past_JJ service_NN cost_NN 169_CD 183_CD Other_JJ unrecognised_JJ costs_NNS 108_CD 135_CD Pension_NN liability_NN under_IN FRS_NNP 17 693 603_CD Profit_NN and_CC loss_NN reserve_NN under_IN FRS17_NNP 2003_CD 2004_CD restated_VBN 000_CD 000_CD Profit_NN and_CC loss_NN reserve_NN per_IN balance_NN sheet_NN 330,147_CD 306,770_CD Pension_NN liability_NN under_IN FRS_NNP 17 693 603_CD Pension_NNP liability_NN under_IN SSAP_NNP 24 416 285_CD Profit_NN and_CC loss_NN reserve_NN under_IN FRS_NNP 17_CD 330,424_CD 307,088_CD Net_JJ assets_NNS under_IN FRS_NNP 17 2003 2004_CD restated_VBN 000_CD 000_CD Net_JJ assets_NNS per_IN balance_NN sheet_NN 63,623_CD 84,870_CD Pension_NN liability_NN under_IN FRS_NNP 17 693 603_CD Pension_NNP liability_NN under_IN SSAP_NNP 24 416 285_CD Net_JJ assets_NNS under_IN FRS_NNP 17_CD 63,346_CD 84,552_CD 2004_CD SkyePharma_NNP Annual_JJ Report_NNP 73_CD 28_CD Acquisitions_NNP Astralis_NNP Limited_NNP On_IN 29_CD December_NNP 2004_CD SkyePharma_NNP signed_VBD conditional_JJ stock_NN purchase_NN and_CC assignment_NN agreements_NNS with_IN two_CD former_JJ Astralis_NNP Directors_NNS to_TO acquire_VB 11,160,000_CD common_JJ shares_NNS and_CC appoint_VB a_DT further_JJ two_CD Directors_NNS representing_VBG SkyePharma_NNP to_TO the_DT Astralis_NNP Board_NNP ._.
As_IN at_IN 29_CD December_NNP 2004_CD the_DT total_JJ SkyePharma_NNP holding_NN was_VBD 25,233,900_CD common_JJ shares_NNS and_CC 20,000_CD warrants_NNS ,_, representing_VBG approximately_RB 34.5_CD %_NN of_IN the_DT common_JJ shares_NNS ._.
The_DT investment_NN has_VBZ been_VBN treated_VBN as_IN an_DT associated_VBN undertaking_NN from_IN 29_CD December_NNP 2004_CD ._.
As_IN of_IN 29_CD December_NNP 2004_CD SkyePharma_NNP began_VBD to_TO exert_VB significant_JJ influence_NN and_CC therefore_RB the_DT equity_NN method_NN of_IN accounting_NN has_VBZ been_VBN adopted_VBN from_IN that_DT date_NN ._.
Goodwill_NN of_IN 13.7_CD million_CD arose_VBD on_IN the_DT acquisition_NN ._.
By_IN consideration_NN of_IN the_DT likely_JJ commercial_JJ life_NN of_IN the_DT Astralis_NNP technology_NN ,_, the_DT Directors_NNS have_VBP determined_VBN that_IN a_DT suitable_JJ period_NN over_IN which_WDT to_TO amortise_VB the_DT goodwill_NN is_VBZ 20_CD years_NNS ._.
See_VB note_NN 12_CD :_: Fixed_JJ asset_NN investments_NNS ._.
Book_NN values_NNS at_IN Accounting_NN policy_NN Provisional_NNP fair_JJ values_NNS at_IN 29_CD December_NNP 2004_CD alignment_NN 29_CD December_NNP 2004 000 000 000_CD Fixed_JJ assets_NNS Intangible_JJ assets_NNS 61_CD 61_CD Tangible_JJ assets_NNS 112_CD 112_CD Investments_NNP 14 14 187 187_CD Current_JJ assets_NNS Stock_NNP 29_CD 29_CD Debtors_NNS 37 521 558_CD Cash_NN and_CC short-term_JJ bank_NN deposits_NNS 1,204_CD 1,204_CD 1,270_CD 521_CD 1,791_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN Other_JJ creditors_NNS 207_CD 207_CD Net_JJ current_JJ assets_NNS 1,063_CD 521_CD 1,584_CD Net_JJ assets_NNS 1,250_CD 521_CD 1,771_CD Capital_NN and_CC reserves_NNS Share_NN capital_NN 27,138_CD 27,138_CD Profit_NN and_CC loss_NN account_NN 25,888_CD 521_CD 25,367_CD Shareholders_NNS funds_NNS 1,250_CD 521_CD 1,771_CD Consideration_NNP 14,342_CD Share_NN of_IN net_JJ assets_NNS at_IN fair_JJ value_NN 34.5_CD %_NN 611_CD Goodwill_NNP 13,731_CD The_DT accounting_NN policy_NN alignment_NN to_TO the_DT net_JJ assets_NNS of_IN Astralis_NNP of_IN 521,000_CD relates_VBZ to_TO an_DT amount_NN recorded_VBN as_IN an_DT expense_NN by_IN Astralis_NNP which_WDT would_MD have_VB been_VBN recorded_VBN as_IN a_DT prepayment_NN according_VBG to_TO SkyePharmas_NNP accounting_NN policies_NNS ._.
During_IN the_DT period_NN 29_CD to_TO 31_CD December_NNP 2004_CD SkyePharmas_NNP share_NN of_IN the_DT loss_NN of_IN Astralis_NNP was_VBD 10,000_CD ._.
The_DT loss_NN of_IN Astralis_NNP for_IN the_DT financial_JJ year_NN was_VBD 10,939,000_CD 2003_CD :_: 3,089,000_CD ._.
74_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 29_CD Related_VBN party_NN transactions_NNS At_IN the_DT end_NN of_IN December_NNP 1998_CD ,_, Ian_NNP Gowrie-Smith_NNP through_IN a_DT family-owned_JJ trust_NN acquired_VBD a_DT 51_CD %_NN interest_NN in_IN 10_CD East_NNP 63rd_NNP Street_NNP Inc._NNP the_DT company_NN which_WDT owns_VBZ 10_CD East_NNP 63rd_NNP Street_NNP ,_, a_DT property_NN in_IN New_NNP York_NNP ._.
In_IN December_NNP 2002_CD Mr._NNP Gowrie-Smith_NNP acquired_VBD a_DT further_JJ 49_CD %_NN interest_NN ._.
SkyePharma_NNP PLC_NNP has_VBZ been_VBN in_IN occupation_NN of_IN approximately_RB half_DT of_IN that_DT property_NN since_IN January_NNP 1997_CD ,_, subject_JJ to_TO tenancy_NN agreements_NNS based_VBN upon_IN independent_JJ valuation_NN ._.
In_IN August_NNP 2003_CD the_DT company_NN took_VBD occupation_NN of_IN the_DT entire_JJ building_NN under_IN an_DT eight-year_JJ tenancy_NN agreement_NN ,_, at_IN which_WDT time_NN the_DT annual_JJ rent_NN was_VBD increased_VBN from_IN $_$ 420,000_CD per_IN annum_NN to_TO $_$ 720,000_CD per_IN annum_NN until_IN August_NNP 2008_CD ,_, and_CC $_$ 942,500_CD per_IN annum_NN from_IN August_NNP 2008_CD to_TO August_NNP 2011_CD ._.
A_DT portion_NN of_IN these_DT premises_NNS is_VBZ currently_RB sub-let_JJ by_IN the_DT Group_NNP ._.
30_CD Subsequent_JJ events_NNS In_IN April_NNP 2005_CD SkyePharma_NNP entered_VBD into_IN an_DT amendment_NN agreement_NN with_IN GlaxoSmithKline_NNP GSK_NNP in_IN respect_NN of_IN Paxil_NNP CR_NNP ._.
Under_IN the_DT terms_NNS of_IN the_DT amendment_NN agreement_NN ,_, GSK_NNP will_MD make_VB a_DT one-time_JJ payment_NN of_IN approximately_RB $_$ 10_CD million_CD ._.
In_IN addition_NN ,_, SkyePharma_NNP will_MD also_RB be_VB entitled_VBN to_TO an_DT increase_NN in_IN the_DT royalty_NN rate_NN from_IN 3_CD %_NN to_TO 4_CD %_NN on_IN actual_JJ net_JJ sales_NNS of_IN Paxil_NNP CR_NNP ,_, with_IN effect_NN from_IN March_NNP 2005_CD ._.
As_IN GSK_NNP has_VBZ been_VBN unable_JJ to_TO supply_VB Paxil_NNP CR_NNP in_IN the_DT US_NNP since_IN March_NNP 2005_CD ,_, GSK_NNP has_VBZ also_RB agreed_VBN to_TO pay_VB SkyePharma_NNP the_DT same_JJ level_NN of_IN royalty_NN on_IN GSKs_NNS budgeted_VBN sales_NNS of_IN Paxil_NNP CR_NNP from_IN March_NNP 2005_CD while_IN the_DT product_NN remains_VBZ off_RP the_DT market_NN subject_NN to_TO other_JJ terms_NNS of_IN the_DT agreement_NN ._.
Approximately_RB 5.0_CD million_CD has_VBZ been_VBN recorded_VBN as_IN royalty_NN income_NN in_IN 2004_CD ._.
On_IN 31_CD May_NNP 2005_CD the_DT Group_NNP announced_VBD that_IN it_PRP had_VBD signed_VBN agreements_NNS for_IN a_DT private_JJ placement_NN of_IN 20_CD million_CD 8_CD %_NN convertible_JJ bonds_NNS ,_, with_IN a_DT first_RB put_VBN after_IN five_CD years_NNS by_IN the_DT holder_NN of_IN the_DT bonds_NNS ,_, and_CC a_DT final_JJ maturity_NN of_IN May_NNP 2025_CD ._.
The_DT bonds_NNS are_VBP expected_VBN to_TO be_VB issued_VBN in_IN June_NNP 2005_CD ._.
The_DT bonds_NNS are_VBP convertible_JJ at_IN the_DT option_NN of_IN the_DT holder_NN into_IN SkyePharma_NNP Ordinary_NNP Shares_NNP at_IN a_DT conversion_NN price_NN of_IN 81_CD pence_NN at_IN any_DT time_NN prior_RB to_TO maturity_NN ._.
Unless_IN previously_RB redeemed_VBN or_CC converted_VBN ,_, the_DT bonds_NNS will_MD be_VB redeemed_VBN by_IN the_DT Group_NNP at_IN their_PRP$ principal_JJ amount_NN in_IN May_NNP 2025_CD ._.
The_DT two_CD convertible_JJ bonds_NNS existing_VBG at_IN 31_CD December_NNP 2004_CD ,_, due_RB in_IN June_NNP 2005_CD and_CC May_NNP 2024_CD ,_, are_VBP not_RB affected_VBN by_IN this_DT transaction_NN ._.
31_CD Principal_NN subsidiary_NN undertakings_NNS %_NN held_VBN of_IN nominal_JJ Company_NN Country_NN of_IN incorporation_NN value_NN and_CC voting_NN rights_NNS Principal_NN activities_NNS SkyePharma_NNP Canada_NNP Inc._NNP ._.
Canada_NNP 100_CD %_NN Research_NN and_CC development_NN SkyePharma_NNP Production_NNP SAS_NNP France_NNP 100_CD %_NN Manufacturing_NNP of_IN pharmaceuticals_NNS SkyePharma_NNP Jersey_NNP Limited_NNP Jersey_NNP 100_CD %_NN Issue_NN of_IN bonds_NNS Krypton_NNP Limited_NNP Gibraltar_NNP 100_CD %_NN Exploitation_NN of_IN intellectual_JJ property_NN SkyePharma_NNP AB_NNP Sweden_NNP 100_CD %_NN Research_NN and_CC development_NN Jago_NNP Holding_NNP AG_NNP Switzerland_NNP 100_CD %_NN Holding_VBG company_NN Jagotec_NNP AG_NNP Switzerland_NNP 100_CD %_NN Exploitation_NN of_IN intellectual_JJ property_NN SkyePharma_NNP AG_NNP Switzerland_NNP 100_CD %_NN Research_NN and_CC development_NN SkyePharma_NNP Holding_NNP AG_NNP Switzerland_NNP 100_CD %_NN Holding_VBG company_NN SkyePharma_NNP Holding_NNP Inc._NNP ._.
US_NNP 100_CD %_NN Holding_VBG company_NN SkyePharma_NNP Inc._NNP ._.
US_NNP 100_CD %_NN Development_NNP of_IN pharmaceuticals_NNS SkyePharma_NNP US_NNP Inc._NNP ._.
US_NNP 100_CD %_NN Development_NNP of_IN pharmaceuticals_NNS and_CC licensing_NN Directly_RB held_VBN by_IN the_DT Company_NN ._.
Full_JJ details_NNS of_IN all_DT subsidiary_NN undertakings_NNS will_MD be_VB attached_VBN to_TO the_DT Companys_NNP Annual_JJ Return_NN to_TO be_VB filed_VBN with_IN the_DT Registrar_NNP of_IN Companies_NNS ._.
